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ABSTRACT
One of the ten greatest public health achievements of the 20th century is the
control of infectious diseases from vaccination according to the Centers for Disease
Control and prevention (CDC). It is recommended by the CDC and the Advisory
Committee on Immunization Practices (ACIP) that everyone 6 months and older
should receive an annual influenza vaccination. The influenza vaccine is a safe and
effective way to prevent the influenza infection and subsequent complications, which
is particularly important in children because it has been shown to reduce influenza
illness in older adults. Currently, the United States utilizes the National Immunization
Survey (NIS-Flu) to provide estimates of annual vaccination rates of children, which
are subject to limitations of survey data such as low response and recall bias.
As of 2009, pharmacists were considered approved influenza vaccinators in all
states.

Pharmacist-administered vaccination improves access to care through

increased convenience with proximity, longer hours, and without the need for an
appointment. Pharmacists have the authority to vaccinate children against influenza
and other vaccine preventable diseases based on different authorization models;
protocols, minimum age restrictions, and/or prescription requirements by state. The
utilization of pharmacists as pediatric vaccinators, as well as the implications of the
restrictions, is not well understood.
Particularly relevant during the current coronavirus disease 2019 (COVID-19)
pandemic, pharmacists will have a more substantial role in the vaccination of children.
In August 2020, the United States Health and Human Services Department (HHS)
granted pharmacists the authority to administer any Food and Drug Administration

(FDA) authorized vaccine to children 3 years of age and older under the “Third
Amendment to Declaration Under the Public Readiness and Emergency Preparedness
Act for Medical Countermeasures Against COVID–19” (PREP Act), which overrides
state-level regulatory mandates. Pharmacists are being recognized as well-positioned
to expand access to all childhood vaccinations in an effort to combat the alarming
decline in all routine pediatric vaccines observed during the onset of the pandemic due
to decreased pediatric physician visits and changes in access to healthcare.
This dissertation provides information that can help to understand the trends in
utilization of pharmacist-administered pediatric influenza vaccine prior to the PREP
Act, as well as determine demographic and clinical characteristics predictive of
utilization of a pharmacy setting for receiving influenza immunizations and determine
if state-level pediatric vaccination rates by a pharmacist impact state level-influenza
diagnoses. For all studies, Optum’s de-identified Clinformatics® Data Mart Database,
a claims data warehouse of commercially insured persons, was used.
In the first manuscript, titled Pharmacist-administered influenza vaccination in
children and corresponding regulations, a summary of pharmacist immunization
authorization models allowing pharmacist-administered influenza immunization by
state from the American Pharmacists Association (APhA) and the National Alliance of
State Pharmacy Associations (NASPA) was prepared along with a retrospective
descriptive epidemiology study to analyze trends of pediatric influenza vaccination by
provider setting using Joinpoint regression. There are three main models under which
pharmacists can administer vaccinations: prescription from physician provider,
vaccination protocol, or pharmacist independent authority (neither physician

prescription nor protocol required). A vaccination protocol specifies which vaccines
can be administered under the protocol and vaccine administration procedures,
including age limitations, usually agreed upon between state-level pharmacist groups,
state-level physician groups, and the state public health department, without the need
for a prescription. In an independent authority model, pharmacists have authority to
administer vaccines without a prescription or protocol. Regardless of pharmacist
authorization models, the minimum age requirements allowing pharmacists to
vaccinate against influenza vary by state. There are 14 states with multiple models
authorizing pharmacist administration of vaccination to children, which commonly
allow children of any age to be immunized by a pharmacist with a prescription, and
after a specified age, the protocol/independent authority model becomes effective and
a prescription is no longer necessary. In our retrospective cohort, almost 4 million
pediatric influenza vaccinations were identified from 2010-2017. The majority took
place in a pediatrician’s office, 87.7%; followed by a pharmacy, 3.2; convenience care,
2.3%; emergency care, 0.8%; and other locations, 6.0%. Pharmacist-administered
pediatric influenza vaccination was more commonly observed in older children, and
less common in the Northeast, where there are more restrictive authorization models.
The utilization trend of pharmacist-administered pediatric influenza vaccination was
increasing significantly by 19.2% each year over the study period, and the utilization
trend of influenza immunization within a pediatrician’s office was slightly decreasing
by 0.9% each year during the same time.
In the second manuscript, titled Pediatric influenza vaccination rates lower than
previous estimates in the United States, the findings from Optum’s Clinformatics®

Data Mart Database were compared to the findings reported by the NIS-Flu survey
estimates from 2010-2017. Recognizing the limitations of survey data, such as use of
random-digit-dialed landline and cellular telephone numbers to conduct surveys,
response bias from low response rates, recall bias, and known overestimations of
vaccination coverage estimates, we sought to describe pediatric influenza vaccination
coverage and trends over time using a retrospective cohort study, descriptive statistics,
and Joinpoint regression.

Current Procedural Terminology, 4th Edition (CPT®)

procedure codes from a commercially insured pediatric population from 2010 to 2017
were captured to build the study population. Over these seven influenza seasons, our
study population had an average annual pediatric influenza vaccination coverage of
33.4%, compared to NIS-Flu reported vaccination coverage estimates of 56.5% during
the same period (p-value <0.0001), resulting in a 51.4% difference between the
commercially insured pediatric study population and the NIS-Flu estimate.
Vaccination coverage was highest in children 6 months-4-years old at 52.6% (versus
68.8% NIS-Flu, p-value <0.0001), and lowest in children 13-17-years old at 20.1%
(versus 42.8% NIS-Flu, p-value <0.0001). Vaccination coverage over time remained
stable in the study population (average annual percent change 1.8%, 95% confidence
interval [CI] -2.3% to 6.0%, p>0.05) versus significantly increasing by 2.8% in NISFlu (95% CI 0.3% to 5.3%, p<0.05). The results from this study validates the need for
more accurate vaccination coverage surveillance. In addition, effective interventions
are needed to increase pediatric influenza vaccination rates to the Healthy People 2020
target of 70%.

In the third manuscript, titled Demographic and clinical predictors of pharmacistadministered pediatric influenza immunization, multivariate logistic regression was
used to determine demographic and clinical characteristics that are predictive to
receiving influenza immunization in a pharmacy setting compared with influenza
vaccination in pediatricians’ offices using CPT codes in Optum from the 2016-2017
influenza season. Our study found 336,841 children received influenza vaccines by a
pharmacist (5.2%) and 94.8% of influenza vaccines administered in pediatricians’
offices (94.8%).

The following predictors of pharmacist-administered influenza

vaccination were identified: older age of 13-17 years old (odds ratio [OR], 91.51; 95%
confidence interval [CI], 73.49-113.94; reference group 6 months to 4 year) and 5-12
years old (OR, 35.41; 95% CI, 28.45-44.07), states with more lenient age restrictions
governing pharmacist-administered influenza vaccination of no age restrictions (OR,
26.68; 95% CI, 21.31-33.41; reference group did not allow pharmacist-administered
pediatric influenza vaccination in children under 18 years old) and minimum age 2-4
years old (OR, 33.76; 95% CI, 26.466-43.07), minimum age 5-12 years old and any
age with prescription (OR, 20.93; 95% CI, 16.75-26.16), minimum age 5-12 years old
(OR, 15.54; 95% CI, 12.43-19.43), minimum age 13-17 years old and any age with
prescription (OR, 13.62; 95% CI, 10.67-17.39), and minimum age 13-17 years old
(OR, 8.95; 95% CI, 6.93-11.55), previous year’s influenza vaccination taking place in
locations of a pharmacy (OR, 22.18; 95% CI, 21.02-23.41; reference group did not
receive influenza vaccine in the year prior), convenience care (OR, 4.15; 95% CI,
3.76-7.58), emergency care (OR, 1.69; 95% CI, 1.33-2.14), and other (OR, 1.13; 95%
CI, 1.01-1.25) and in patients living in the South (OR, 2.02; 95% CI, 1.82-2.25;

reference Northeast), Midwest (OR, 1.60; 95% CI, 1.45-1.77), and West (OR, 1.38;
95% CI, 1.24-1.55), and routine health examination or follow up appointment in the 6month baseline period (OR, 1.59; 95% CI, 1.53-1.65). Alternatively, the following
were predictive of pediatricians’ office pediatric influenza vaccination: previous
diagnosis of acute upper respiratory infection (OR, 0.91; 95% CI, 0.83-0.99);
attention-deficit/hyperactivity disorder (ADHD) (OR, 0.90; 95% CI, 0.83-0.98); strep
sore throat (OR, 0.87; 95% CI, 0.79-0.96); cough (OR, 0.85; 95% CI, 0.77-0.94); fever
(OR, 0.85; 95% CI, 0.76-0.95); obesity (OR, 0.84; 95% CI, 0.73-0.98); otitis media
(OR, 0.79; 95% CI, 0.70-0.89); and severe developmental delay (OR, 0.66; 95% CI,
0.53-0.83).

The strongest drivers of pharmacist-administered pediatric influenza

vaccination were older age, more lenient minimum age restrictions, and previous
influenza vaccination in a pharmacy, which is particularly important during the
COVID-19 pandemic, where pharmacists are likely to be more involved in vaccinating
children, which may result in sustained changes in pediatric vaccination practices.
In the fourth and final manuscript, titled Increased proportions of state-level
pediatric pharmacist-administered influenza immunization decrease influenza
diagnoses, the proportion of children vaccinated against influenza by pharmacists and
the proportion diagnosed with influenza were aggregated at the state-level during the
2016-2017 influenza season, along with potential confounders. The association
between state-level pediatric pharmacist-administered influenza vaccination and
influenza diagnoses was assessed using backward manual stepwise beta regression.
The proportion of children that received an influenza vaccine in a pharmacy varied
widely by state. At a state level, we found that influenza diagnoses among children

decrease by 6.2% (p=0.0369) per every additional 1% of children vaccinated by a
pharmacist, after controlling for potential confounding factors.

Fewer influenza

diagnoses were observed in states with higher pharmacist-administered pediatric
influenza vaccination. Decreasing influenza diagnoses can help decrease the
significant burden of influenza in children and throughout communities. Additionally,
now that pharmacists have been granted expanded authority to vaccination children
due to the COVID-19 pandemic, pharmacists play a key role as vaccine providers and
have the ability to reduce rates of all vaccine-preventable diseases among children.
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PREFACE
This dissertation is written in the Manuscript Format based on the guideline
provided by the University of Rhode Island Graduate School. A total of four
manuscripts were prepared that encompass pharmacist-administered pediatric
influenza vaccination utilization and corresponding regulations (manuscript I),
pediatric influenza vaccination rates (manuscript II), demographic and clinical
predictors of pharmacist-administered pediatric influenza immunization (manuscript
III) and the impact of state-level pharmacist-administered influenza vaccination rates
among children on state level influenza diagnoses (manuscript IV).
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MANUSCRIPT 1

Pharmacist-administered influenza vaccination in children and corresponding
regulations

Article Summary: While only 3.2% of the 3,937,376 pediatric influenza vaccinations
from 2010-2017 were pharmacist-administered in a claims database, pharmacistadministration increased significantly by 19.2% per year.
What’s Known on This Subject: Pharmacists are authorized to administer vaccines
to children in the US under state-governed Pharmacist-Authorization models,
however, minimum age requirements, vaccination protocols, and/or prescription
requirements may limit pharmacist-administered pediatric vaccination. There are
limited published estimates of pharmacist-administered pediatric influenza
vaccination.
What This Study Adds: From 2010-2017, only 3.2% of the 3,937,376 pediatric
influenza vaccination claims from a claims database were administered by a
pharmacist, which increased significantly by 19.2% each year and were more common
in older children and in states with fewer restrictions.

Target Journal: American Journal of Public Health

1

1.1 ABSTRACT
Background and Objectives: Though pharmacists are vaccine providers in the
United States, individual state regulatory mandates, including minimum age,
vaccination protocols, and/or prescription requirements may limit pharmacistadministered pediatric vaccination.

Therefore, the purpose of our study was to

evaluate pharmacist-administered pediatric influenza vaccination rates in a claims
database and corresponding state-level pharmacist pediatric vaccination authorization
models.
Methods: Our retrospective cohort study assessed provider setting for influenza
vaccination procedure codes among children in Optum’s de-identified Clinformatics®
Data Mart Database from 2010-2017. State-level pharmacist-administered pediatric
influenza vaccination and corresponding regulations were assessed, as were time
trends using Joinpoint regression.
Results: Of the 3,937,376 pediatric influenza vaccinations identified over the study
period, only 3.2% were pharmacist-administered (87.7% pediatrician offices, 2.3%
convenience care clinics, 0.8% emergency care, and 6.0% other locations).
Pharmacist-administered pediatric influenza vaccination was more commonly
observed in older children (mean age 12.65 ± 3.26 years). Pharmacist-administered
influenza vaccination increased significantly by 19.2% annually over the study period
(95% confidence interval 9.2%-30.2%, p<0.05). The Northeast, with more restrictive
authorization models, represented only 2.2% (n=2,816) of all pharmacist-administered
pediatric influenza vaccinations.

2

Conclusions: Though pharmacist-administered pediatric influenza vaccination is
permitted in all states, utilization remains low. Providing children with greater access
to vaccination with less restrictions could help increase overall vaccination rates. Due
to the COVID-19 pandemic and the Public Readiness and Emergency Preparedness
Act, pharmacists will play a major role in vaccinating children, and future research
should evaluate uptake of pharmacist-administered pediatric vaccination, including
pediatric

COVID-19

vaccination

3

by

pharmacists.

1.2 INTRODUCTION
Although annual influenza vaccine is recommended by the Centers for Disease
Control and Prevention (CDC) and the Advisory Committee on Immunization
Practices (ACIP) for children 6 months and older (1-6), there is continued hesitancy
towards influenza vaccination (7).

The CDC has consistently reported pediatric

vaccination rates that are lower than the Healthy People 2020 target of 70% for
children aged 6 months through 17 years (8, 9), potentially due to barriers in access
(10). According to the National Immunization Survey (NIS), a national telephone
survey conducted by the CDC to assess vaccination coverage among children (6
months through 17 years) (11), pediatric influenza vaccination rates over the past
decade have increased from 51.0% in 2010-2011 to 63.8% in 2019-2020 (12).
While vaccines are often administered in primary care or pediatricians’ offices
by medical personnel, under the supervision of a physician, pharmacists have been
approved to administer influenza vaccines to adults in all 50 states since 2009 (13).
However, regulations enabling pharmacist-administered vaccination also carry
restrictions for children, such as state-specific minimum age requirements and other
regulatory limitations, including restricted lists of allowed vaccinations under these
mandates (14-16). Vaccination outside of pediatricians’ offices improves vaccine
access through increased convenience, with expanded hours and without the need for
an appointment (16).

Additionally, 93% of patients live within five miles of a

pharmacy and most patients have positive experiences with their pharmacy (17, 18).
To date, there are limited published estimates of pharmacist-administered
pediatric influenza vaccination. According to NIS-Flu, vaccination in a pharmacy was
4

reported for 5.5% of pediatric influenza vaccinations in the 2017-2018 flu season
(66.8% doctor’s offices, 16.2% clinics and health centers, 4.3% hospitals, 3.8%
schools. 1.9% health departments, and 1.5% other settings) (19).

Due to the

limitations of NIS-Flu, including overestimation of pediatric influenza vaccination and
other biases due to the nature of survey methods (11), it is unclear whether these
estimates of pharmacist-administered vaccination are accurate. Further, state-level
variations in pharmacist-administered pediatric influenza vaccination remain
unknown, as does the influence of state-level pharmacist vaccination authorization
models.
As such, the objective of this study was to evaluate state-level pharmacistadministered pediatric influenza vaccination authorization models alongside statelevel pharmacist-administered pediatric influenza vaccination rates and time trends
using a claims database of commercially insured persons.

5

1.3 METHODS
We assessed the distribution of vaccine providers among vaccinated children
using a health claims database with enrollees from all 50 states and the District of
Columbia, Optum’s de-identified Clinformatics® Data Mart Database.

Using a

retrospective cohort study design, we evaluated pediatric influenza vaccinations by
vaccine provider setting and corresponding variations in patient characteristics. The
study population included children with an influenza vaccination record between July
1, 2010 to June 30, 2017 identified from Current Procedural Terminology, 4th Edition
(CPT®) procedure codes found in Supplementary Table 1 and under 18 years of age at
the time of the influenza vaccination claim. Vaccinations were assigned to influenza
seasons, where time was divided into 12-month periods from July 1 through June 30
of the following year (20). For each season, pediatric patients with full continuous
enrollment for the 12 months of that season and with at least one influenza CPT®
code, were for selected for inclusion (20). Only the first influenza vaccination within
a season was included, while patients with missing year of birth, state, or sex were
excluded.
Vaccine provider setting was categorized as pediatricians’ offices, which
included family medicine and primary care settings, pharmacist-administered,
convenience care clinic, emergency care, and other, which included locations such as
schools or other immunization centers. Of note, pharmacy-based vaccination did not
include healthcare clinics located in retail pharmacies (e.g. CVS MinuteClinic) as
those were categorized under convenience care. Within each vaccine provider setting,
we assessed the distribution of age and age group, sex, region, and pharmacist6

authorization minimum age restriction. Both mean and median age were assessed, as
well as distribution by age groups per the NIS-Flu categorization of 6-23 months, 2-4
years, 5-12 years, and 13-17 years (19). States were grouped into regions per the 2010
United States Census Bureau of Regions and Division categorizations (21) as regional
vaccination coverage can vary (22). We assessed the distribution of influenza vaccine
provider setting among vaccinated children, and calculated pharmacist-administered
pediatric influenza vaccination rates for each state (the proportion of vaccinated
children with pharmacy provider setting within each state).
A grey literature search was performed to identify state-level regulations
regarding pharmacist-authority to administer influenza vaccines to children. Grey
literature search methods consisted of a Google search of key terms, including
“pharmacist administered pediatric influenza vaccination” and “minimum age
restrictions”. Search results were assessed for state-level regulations. One document
was selected for inclusion after full-text review, authored by the American
Pharmacists Association (APhA) and the National Alliance of State Pharmacy
Associations (NASPA), due to the corresponding timeframe of the document and the
study data (14). Minimum age restrictions were assessed for all authorization models
within each state. Pharmacist-administered pediatric influenza vaccination rates were
then averaged among states with corresponding authorization models and minimum
age requirements.
Statistical Analysis
Demographic characteristics of vaccinated children in each provider setting
were compared with the pediatricians’ office setting using chi-square tests, or

7

Wilcoxon rank sum test as appropriate in SAS (version 9.4, SAS Institute Inc., Cary,
NC). Time trends in pediatric vaccination were assessed by vaccination provider
setting, and stratified by age, with Joinpoint regression, over the seven vaccination
seasons with each season being an equally weighted interval. Average annual percent
change (AAPC) and corresponding 95% confidence intervals by vaccination provider
setting were calculated using the Joinpoint Regression Program, version 4.7.0.0
(National Cancer Institute, Bethesda, MD). Statistical significance was considered
p<0.05.
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1.4 RESULTS
Pharmacist-administered pediatric influenza vaccination rates
Our study included 3,937,376 influenza vaccinations among children over
seven influenza seasons, from 2010 to 2017 (Table 1).

Of the total influenza

vaccinations, most occurred in pediatricians’ offices (87.7%, n=3,451,658), followed
by pharmacist-administered (3.2%, n=125,709), convenience care (2.3%, n=90,304),
and emergency care (0.8%, n=32,499).
Mean and median ages (Table 1 and Figure 1) were highest among those
vaccinated by a pharmacist (mean age 12.7 ± 3.3 years), followed by convenience care
(mean 9.7 ± 4.2 years), other locations (mean 8.4 ± 4.9 years), emergency care (mean
8.2 ± 4.6 years), and youngest among those vaccinated in pediatricians’ offices (mean
7.0 ± 4.8 years).

Within the pharmacy setting, 56.3% (n=70,806) of influenza

vaccinations were among children 13-17-year-old age group. In comparison, only
16.9% (n=582,152) of children that were vaccinated in a pediatrician’s office were 1317 years old.
Compared to the pediatricians’ office setting, the distribution of pediatric
influenza vaccinations by sex differed significantly for the pharmacy (p=0.004) and
convenience care (p<0.0001) settings.

Influenza immunization of males was

marginally higher than females in all settings including the pharmacy, except for
convenience care.
Statistically significant differences were observed in the distribution of
geographic region when comparing pediatrician's office to the other vaccine provider
settings. Most vaccinations occurred in the South, for vaccination in the pediatricians’
9

office setting (39.5%), pharmacy (45.0%), and convenience care (53.0%), whereas
most vaccinations in emergency care (50.0%) and other settings (36.7%) occurred in
the West. Of all pharmacist-administered pediatric influenza vaccinations, only 2.2%
(n=2,816) occurred in the Northeast, as Connecticut, Massachusetts, New York, and
Vermont do not allow pharmacist-administered pediatric influenza vaccination.
Over the study period, the average annual percent change in pharmacistadministered pediatric influenza vaccination increased significantly by 19.2% (95% CI
9.2 to 30.2, p<0.05), from 1.5% in the 2010-2011 season to 4.2% in the 2016-2017
season (Figure 2). During the same period, the average annual percent change in
pediatric influenza vaccination in pediatricians’ office decreased significantly by 0.9%
(95% CI -1.3 to -0.5, p<0.05).

A separate analysis was performed comparing

influenza vaccination coverage trends from pediatricians’ offices and pharmacies,
stratified by age group, over the same period (Figure 3). For all age groups (6 months
to 4 years, 5 to 12 years, and 13 to 17 years), there was a significant decreasing trend
in utilization of pediatricians’ offices as influenza vaccination providers; 6 months to 4
year old AAPC -0.3% (95% CI -0.5% to -0.2%, p<0.05), 5 to 12 year old AAPC 1.0% (95% CI -1.2% to -0.7%, p<0.05), and 13 to 17 year old AAPC -1.5% (95% CI 2.7% to -0.4%, p<0.05).

The average annual percent change in pharmacist-

administered pediatric influenza vaccination increased significantly in the 5 to 12
years old age group by 17.12% (95% CI 8.6 to 26.3, p<0.05) and the 13 to 17 year old
age group by 15.2% (95% CI 6.5 to 24.6, p<0.05). The average annual percent change
in pharmacist-administered pediatric influenza vaccination in the 6-month to 4 year
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old age group also showed an increasing trend by 2.5% (95% CI -10.6 to 17.5,
p>0.05), however, non-significant.
Pharmacist-administered pediatric influenza vaccination authorization models
There are three main models under which pharmacists can administer
vaccinations (Table 2): prescription from physician provider, vaccination protocol, or
pharmacist independent authority. A prescription from a provider is handled on a
case-by-case basis. A vaccination protocol covers all children within the state and
specifies which vaccines can be administered under the protocol and vaccine
administration procedures, including age limitations, usually agreed upon between
state-level pharmacist groups, state-level physician groups, and the state public health
department.

Under a vaccination protocol, no prescription is required.

In an

independent authority model, pharmacists have the authority to prescribe and
administer the vaccine to the child without a protocol or physician prescription (23).
Some states follow multiple models, which commonly allow children at a specified
age to be vaccinated by a pharmacist under a protocol/independent authority, and
children below the minimum age restriction require a prescription (14, 23).
Regardless of pharmacist authorization models (Table 2), the minimum age
requirements allowing pharmacists to vaccinate against influenza vary by state (Figure
4). Arizona, where pharmacists are authorized to administer influenza vaccinations
under two authorization models, the least restrictive being pharmacists’ independent
authority beginning at 3 years of age, had the highest percent of children vaccinated by
a pharmacist at 7.8%. Following Arizona were states where there is no age limit; New
Mexico (6.9%), Colorado (6.6%), Nevada (6.1%), Mississippi (6.1%), Oklahoma
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(5.9%), Michigan (5.5%), and Nebraska (5.0%).

The pharmacist-administered

influenza vaccination rate in Texas was 5.6%, which allows pharmacist-administered
influenza vaccination for children 7 years and older under a protocol and at any age
with a prescription.

Hawaii had the lowest pharmacist-administered influenza

vaccination (0.1%), as the mandate only allows pharmacist-administered influenza
vaccination in children 14 years and older with a physician prescription. As of July
2016 (14), six states did not allow pharmacist-administered influenza vaccination for
children of any age under 18, which included Connecticut, Florida, Massachusetts,
New York, Vermont, and West Virginia.
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1.5 DISCUSSION
To our knowledge, this is the first study to evaluate pharmacy-based
immunization rates among a commercially insured pediatric population in the United
States. Our study found that over seven influenza seasons from 2010-2017, only 3.2%
of all influenza vaccinations occurred in a pharmacy setting and the majority of
pediatric influenza vaccinations were found to be administered in pediatricians’
offices, 87.7%. However, also during this time, administration of pediatric influenza
vaccines by pharmacists increased significantly by 19.2% each year. We observed a
slight but significant decrease over time in influenza vaccinations in pediatricians’
offices across all age groups, and a larger increase in vaccinations by pharmacists. A
potential explanation is that pharmacist-administered influenza vaccination offers
vaccination access to children who may not have otherwise been vaccinated from their
pediatrician and is helping to increase overall pediatric influenza vaccination rates.
Pharmacist-administered influenza vaccination was more common among
older children and where administration laws allow have less restrictive age
limitations around pharmacist-administered pediatric vaccination. States with more
restrictions and older minimum age requirements, had lower rates of pharmacistadministered influenza immunization.
According to NIS-Flu data for the 2017-2018 influenza season, 5.5% of all
children ages 6 months to 17 years old were immunized in a pharmacy setting, and
66.8% of children were vaccinated in their doctor’s office (19), while 28.3% of adults
were vaccinated in a pharmacy and 34.7% in physicians’ offices (24). NIS-Flu is a
national dual landline and cellular list-assisted random-digit-dialed telephone survey
13

of households.

This self-reported survey data is subject to recall bias and non-

response bias from low response rates (11). The findings presented from our cohort
study were from claims data from a commercially insured population with records of
actual influenza vaccine administrations by provider setting and are not subject to
survey data biases.
As also reported by NIS-Flu data, influenza vaccine setting varied by age
group in our findings; for example children less than 5 years old utilized pediatricians’
offices more frequently than other settings and children 13-17 years old utilized a
pharmacy setting more frequently (19). As children get older, they are less likely to
receive the influenza vaccine, which has been a consistent trend observed by NIS-Flu
since 2010 (19).

For example, in the 2015-2016 influenza season, NIS-Flu

vaccination coverage estimates within age groups were as follows; 6 months-23
months 75.3%, 2-4 years 66.8%, 5-12 years 61.8%, and 13-17 years 46.8% (24). This
may be due to a decrease in the number of physician visits as children get older.
Administration of annual influenza vaccine typically occurs around the same time
every year, in late fall or early winter, which may not align with a child’s annual
routine examination. A pharmacy can satisfy increased interest in vaccination outside
of a pediatrician’s office.
A main objective of pharmacist-administered influenza immunization is to
expand access to vaccination through increased accessibility, convenience, extended
hours, and widespread locations (8) for patients who find it difficult to reach
traditional healthcare services, which could in turn increase vaccination coverage for
all ages (18). Pharmacies are open for longer hours during the week and are also
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available on weekends and holidays. A study from the 2011-2012 influenza season
estimated that over 30% of all adult vaccinations administered at a Walgreens
pharmacy chain were during evenings, weekends, or holidays (25). Another important
role pharmacists play is through vaccine advocacy (26). Pharmacists were more
successful than traditional healthcare providers in administering vaccines to patients
that were not current in their immunizations after performing an immunization needs
assessment in adults (8). However, it can be more costly and less efficient when
pharmacists require a prescription from a healthcare provider to administer vaccines to
children (23).
Increasing influenza vaccination among children is critical to controlling
influenza outbreaks.

It has been found that vaccinating children, in addition to

protecting other children, protects the entire community by limiting the transmission
of the virus, in particular to vulnerable populations such as the elderly and
immunocompromised (27). Expansion of the ability for pharmacists to administer
vaccines and increase vaccination rates among children, for influenza and other
epidemics, is critical for public health.
As of August 2020, pharmacists in all states have been authorized by the U.S.
Health and Human Services Department (HHS) to administer any FDA authorized
vaccines to children aged 3 to 18 under the “Third Amendment to Declaration Under
the Public Readiness and Emergency Preparedness Act for Medical Countermeasures
Against COVID–19” (PREP Act) for the duration of the COVID-19 pandemic (28).
Due to the current COVID-19 pandemic, there has been an alarming decline in routine
pediatric vaccines due to decreased pediatric physician visits and changes in
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healthcare access (such as closed offices or limited hours, and corresponding increases
in virtual visits) (28, 29). Data collected from the Vaccines for Children program, a
national program that provides vaccines to approximately 50% of children in the
United States (29), showed that physicians participating in the program ordered
approximately 2.5 million fewer non-influenza routine vaccines and 250,000 less
measles-containing vaccines, and the decline was more prominent in children 2-18
years old (29, 30). In the declaration, pharmacists are recognized as being well
positioned to expand access to all childhood vaccinations, which can help combat the
public health threat of declining vaccination rates (28).
As this amendment is recent and parents may not be aware of this change, it is
unclear to what extent parents will elect to have their children vaccinated by a
pharmacist.

Future efforts should monitor uptake of pharmacist-administered

pediatric vaccination to determine utilization rates, and whether increased vaccination
by pharmacists compensates for reductions in pediatrician’s office vaccinations. It is
possible that societal vaccination practices may shift as a result of this expansion in
care, similar to changes observed in satisfaction with and therefore preference in some
cases for virtual healthcare (31).

It remains unknown how long pharmacist-

administered vaccination authorization will remain under the PREP Act. Studying its
long-term impacts will be important for advocacy efforts of continued expanded
access to vaccination for children in the United States at their local pharmacies,
particularly if pharmacists become the primary vaccine provider for pediatric COVID19 vaccines.
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Limitations
The population studied here was limited to pediatric patients from one claims
database within the United States, compiled from vaccination procedure codes. As
such, our study did not assess influenza vaccination by provider setting among
pediatric patients with Medicaid, which is estimated to include approximately 30
million children nationally, or other private health plans (32), and distributions by
vaccine provider may vary in these populations.

Missing from our cohort are

influenza vaccinations that were not processed through health insurance, such as
through free public health clinics.

Due to the nature of the database, age was

calculated using the date of vaccination and the patient’s year of birth. In patients that
are vaccinated in early fall and have birthdays occurring later in the year, the patient
would be considered one year older if they were vaccinated before their birthday. The
study relies on the accuracy and consistency of provider categorization in the source
data to indicate vaccine administration setting.

Vaccinations in other locations,

including non-specific locations were uncommon, encompassing 6.0% of pediatric
influenza vaccination in our study population. Another major limitation of our study
was that the study database did not include race, and therefore we could not assess
trends in vaccination setting by race or ethnicity. It is important that future research
evaluate vaccination setting by race and ethnicity, as this may provide insight into
vaccination disparities and opportunities to develop interventions to improve influenza
vaccination rates in children. Additionally, we could not assess parent willingness
(33), access to care, socioeconomic status, and education (7) which may also influence
where children themselves or their parent elect to have them vaccinated.
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Overall pediatric influenza vaccination rates vary by state (19), as did the
proportion of children within this dataset of the total state pediatric population, which
we did not assess in this study. Pharmacist authorization models were assessed as of
July 2016, and therefore changes in authorization models may have occurred over the
7-year period when pediatric influenza vaccination claims were assessed. Lastly, due
to the large population size, some statistically significant differences were observed
that are not necessarily clinically meaningful, particularly marginal differences in sex
among providers.
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1.6 CONCLUSION
Although pharmacist-administered influenza vaccination has been allowed in
all 50 states for over 10 years (13), various state-level restrictions on pharmacistadministered pediatric influenza vaccination, such as protocols, prescription
requirements, and minimum age restrictions, impact uptake of pharmacistadministered pediatric influenza vaccination.

Of the nearly 4 million, pediatric

influenza vaccinations included in our study, only 3.2% were pharmacistadministered.

We found that annually, utilization of pharmacists as influenza

vaccinators of children increased significantly by 19.2% each year over the 7-year
study period.

Providing children with greater access to vaccinations with less

restrictions could help increase influenza vaccination rates to get closer to the Healthy
People 2020 target of at least 70% for children (9). Additionally, during the current
COVID-19 pandemic, pharmacists will be instrumental for overcoming the profound
decrease in all pediatric vaccination rates observed during the pandemic (28). Future
research should evaluate uptake of pharmacist-administered pediatric vaccination for
influenza, other childhood vaccines, and pediatric COVID-19 vaccination when it
becomes available.
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1.8 TABLES AND FIGURES
Table 1. Pediatric influenza vaccinations by vaccine provider setting

Demographic Characteristics

Age (Mean ± SD)

Pediatrician
Office
n = 3,451,658

n = 125,709

Convenience
Care
n = 90,304

(87.7%)

(3.2%)

Pharmacy

Emergency Care

Other

n = 32,499

n = 237,206

(2.3%)

(0.8%)

(6.0%)

24

7.04 ± 4.81

12.65 ± 3.26*

9.73 ± 4.23*

8.21 ± 4.64*

8.37 ± 4.90*

6 months - 2 years

768,750 (22.3%)

87 (0.1%)*

2,784 (3.1%)*

4,092 (12.6%)*

35,227 (14.9%)*

2 - 4 years

520,856 (15.1%)

1,314 (1.1%)*

8,775 (9.7%)*

4,221 (13.0%)*

28,300 (11.9%)*

5 - 12 years

1,579,900 (45.8%)

53,502 (42.6%)*

51,919 (57.5%)*

17,178 (52.9%)*

115,465 (48.7%)*

13 - 17 years

582,152 (16.9%)

70,806 (56.3%)*

26,826 (29.7%)*

7,008 (21.6%)*

58,214 (24.5%)*

Female

1,687,410 (48.9%)

62,095 (49.4%)*

45,513 (50.4%)*

15,959 (49.1%)

116,650 (49.2%)*

Male

1,764,248 (51.1%)

63,614 (50.6%)*

44,791 (49.6%)*

16,540 (50.9%)

120,556 (50.8%)*

Age Group†

Sex†

Region†
Midwest1

969,480 (28.1%)

28,548 (22.7%)*

24,134 (26.7%)*

6,178 (19.0%)*

82,370 (34.7%)*

Northeast2

486,435 (14.1%)

2,816 (2.2%)*

6,934 (7.7%)*

1,775 (5.5%)*

17,536 (7.4%)*

South3

1,361,550 (39.5%)

56,517 (45.0%)*

47,898 (53.0%)*

8,288 (25.5%)*

50,333 (21.2%)*

West4

634,193 (18.4%)

37,828 (30.1%)*

11,338 (12.6%)*

16,258 (50.0%)*

86,967 (36.7%)*

State-Level Pharmacist Authorization Model, Age Restrictions†
25

No age restriction

822121 (23.8%)

46238 (36.8%)*

14429 (16.0%)*

17369 (53.4%)*

94696 (39.9%)*

Min age 2-4 years old

80514 (2.3%)

7509 (6.0%)*

4899 (5.4%)*

85 (0.3%)*

3119 (1.3%)*

784427 (22.7%)

39765 (31.6%)*

21981 (24.3%)*

3477 (10.7%)*

33708 (14.2%)*

1031281 (29.9%)

22207 (17.7%)*

23692 (26.2%)*

7701 (23.7%)*

79558 (33.5%)*

175394 (5.1%)

6099 (4.9%)*

8103 (9.0%)*

863 (2.7%)*

10549 (4.5%)*

Min age 13-17 years old5

103572 (3.0%)

2652 (2.1%)*

5086 (5.6%)*

363 (1.1%)*

3003 (1.3%)*

Min 18 years old

454349 (13.2%)

1239 (1.0%)*

12114 (13.4%)*

2641 (8.1%)*

12573 (5.3%)*

Min age 5-12 years old,
Any age with Rx
Min age 5-12 years old
Min age 13-17 years old,
Any age with Rx

† No. (%)
* P <0.05

Demographic characteristics of vaccinated children in each provider setting were compared with the pediatricians’ office setting using
chi-square tests (age group, sex region, state-level pharmacist authorization model age restrictions) and Wilcoxon rank sum test (age).
Ohio, Indiana, Michigan, Illinois, Wisconsin, Missouri, Iowa, Minnesota, North Dakota, South Dakota, Nebraska, Kansas
Maine, New Hampshire, Vermont, Massachusetts, Rhode Island, Connecticut, New York, New Jersey, Pennsylvania
3
West Virginia, District of Columbia (DC), Virginia, North Carolina, Kentucky, Maryland, Delaware, Tennessee, South Carolina, Georgia,
Florida, Alabama, Mississippi, Arkansas, Louisiana, Oklahoma, Texas
4
Montana, Wyoming, Colorado, Utah, Idaho, Nevada, Washington, Oregon, California, Alaska, Hawaii, New Mexico, Arizona
5
Includes Hawaii, where a prescription is required for pharmacist-administered influenza vaccination
1
2
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Table 2. Pharmacist-administered pediatric influenza vaccination authorization
models and average pharmacist-administered pediatric influenza vaccination rates,
2010-2017

Authorization Patient age
model
limitations

State(s)

Alaska
Any Age

New Hampshire
New Mexico

6 months*
3
Pharmacist

6

independent
authority1

Average
pharmacistadministered
pediatric
influenza
vaccination
rates, by
authorization
model and age
restriction

4.0%

Virginia1,3
Arizona1,2
California

5.6%

1,2

Idaho

2.7%
3.3%

Louisiana1,3
7

Average
pharmacistadministered
pediatric
influenza
vaccination
rates, by
authorization
model

Maine

3.3%

Oregon1,3
Wyoming

9

Maryland

2.9%

Montana
12

New Jersey1,3

1.4%

South Carolina1,3
Protocol

2

Any Age

Alabama

4.5%

California1,2

27

3.5%

Colorado
Delaware
Michigan
Mississippi
Nebraska
Nevada
Oklahoma
South Dakota
Tennessee
Utah
Washington
5

North Dakota

0.3%

Arizona1,2
Iowa2,3
6

3.7%

Kansas
Minnesota
Wisconsin
Arkansas

7

Ohio

3.6%

Texas2,3
Kentucky2,3
9

Pennsylvania

1.3%

Rhode Island
10

Illinois

3.3%

11

Indiana2,3

3.3%

28

12

District of Columbia2,3
Missouri

2,3

2.2%

13

Georgia2,3

3.0%

14

North Carolina

2.3%

District of Columbia2,3
Georgia2,3
Indiana2,3
Iowa2,3
Kentucky2,3
Any Age

Louisiana1,3

3.2%

Missouri2,3

Prescription3

2.8%

Oregon1,3
South Carolina1,3
Texas2,3
Virginia1,3
6

New Jersey1,3

0.9%

14

Hawaii

0.1%

Note: Pharmacist-administered pediatric influenza vaccination authorization models as of July
2016 [14]. Models are not mutually exclusive for each state, as states may have different
authorization models for different age groups. 14 states use multiple models authorizing
pharmacist administered vaccination of children. Commonly prescriptions are used to allow
children of any age to be vaccinated by a pharmacist, and then after a specified age, the
protocol/independent authority model takes over and a prescription is no longer needed.
*Influenza vaccine is recommended in children 6 months of age and older.
1
Pharmacists have authority to administer vaccines without a protocol or prescription.
2
Vaccination protocol specifies vaccine administration procedures usually agreed upon
between state-level pharmacist and physician groups and the state public health department.
3
Prescription from physician provider is required prior to administration of vaccine by
pharmacist.
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Figure 1. Median age of pediatric influenza vaccination by vaccine provider setting

Figure 1. Median ages for the pediatric influenza vaccination settings are shown as the center
bar, the box represents the third quartile (Q3) through the first quartile (Q1), and the range of
the data from maximum to minimum are shown in the vertical lines Age significantly differed
among all pediatric vaccination providers when compared to pediatricians’ offices using the
Wilcoxon rank sum test (p<0.0001).
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Figure 2. Trends in pediatric influenza vaccination by provider setting, 2010-2017
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Pediatrician (AAPC -0.9%, 95% CI -1.3% to -0.5%)*
Pharmacy (AAPC 19.2%, 95% CI 9.2% to 30.2%)*
Convenience Care (AAPC 4.8%, 95% CI -1.5% to 11.6%)
Emergency Care (AAPC 8.9%, 95% CI -2.4% to 21.6%)
Other (AAPC 4.5%, 95% CI 3.1% to 6.0%)*

Note: AAPC, average annual percent change; CI, confidence interval. The Joinpoint Regression Program was used to calculate average annual
percent change (AAPC) and 95% CI. *Significant trend at P<0.05. Refer to left y-axis for influenza vaccination in pediatricians’ offices. Refer to
right y-axis for all other influenza vaccine provider settings.

Figure 3. Trends in pediatric influenza vaccination by vaccine provider setting and age group, 2010-2017
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6 months to 4 years;
5 to 12 years;
13 to 17 years;

Pediatrician (AAPC -0.3%*, 95% CI -0.5% to -0.2%)
Pediatrician (AAPC -1.0%*, 95% CI -1.2% to -0.7%)
Pediatrician (AAPC -1.5%*, 95% CI -2.7% to -0.4%)

Pharmacy (AAPC 2.5%, 95% CI -10.6% to 17.5%)
Pharmacy (AAPC 17.1%*, 95% CI 8.6% to 26.3%)
Pharmacy (AAPC 15.2%*, 95% CI 6.5% to 24.6%)

Note: AAPC, average annual percent change; CI, confidence interval. The Joinpoint Regression Program was used to calculate average annual
percent change (AAPC) and 95% CI. *Significant trend at P<0.05. Refer to left y-axis for influenza vaccination in pediatricians’ offices and right
y-axis for pharmacy.

Figure 4. Pharmacist-administered pediatric influenza vaccination minimum age restrictions (as of July 2016) and pharmacistadministered influenza vaccination rates by state, 2010-2017
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Note: Utilized youngest age of least restrictive authorization model for states with multiple authorization models.

MANUSCRIPT 2

Pediatric influenza vaccination rates lower than previous estimates in the United
States

Article Summary: The average annual influenza vaccination coverage was 51.4%
lower in our study population of commercially insured children compared to estimates
reported by NIS-Flu from 2010-2017.
What’s Known on This Subject: Currently, estimates of influenza vaccination
coverage among children in the United States are determined from national surveys.
Survey study designs have known limitations such as recall bias and response bias,
resulting in recognized overestimated influenza vaccination coverage estimates.
What This Study Adds: From 2010-2017, significant differences in the average
annual pediatric influenza vaccination coverage were observed between NIS-Flu
survey data and vaccination claim records. More accurate vaccination coverage
surveillance is needed, along with interventions to increase pediatric influenza
vaccination rates.

Target Journal: American Academy of Pediatrics
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2.1 ABSTRACT
Background:

Annually, pediatric influenza vaccination coverage estimates are

ascertained from health surveys, such as the National Immunization Survey (NIS-Flu).
From 2010-2017, vaccination coverage among children ranged from 51-59%.
Recognizing the limitations of national health survey data, we sought to describe
temporal trends in pediatric influenza vaccination coverage, and demographic
differences among a commercially insured large national cohort from 07/01/201006/30/2017.
Methods: Influenza vaccination coverage was assessed among children (<18 years)
with continuous enrollment in the de-identified Optum Clinformatics® Data Mart
Database, and from NIS-Flu. Time trends in vaccination coverage were assessed using
Joinpoint regression, overall and stratified by age group, sex, and geographic region.
Results: The average annual pediatric influenza vaccination coverage was 33.4% in
our study population versus 56.5% reported from NIS-Flu during the same period (pvalue <0.0001). Vaccination coverage was highest in children 6 months-4-years old at
52.6% (versus 68.8% NIS-Flu, p-value <0.0001), and lowest in the 13-17-year old age
group at 20.1% (versus 42.8% NIS-Flu, p-value <0.0001). Vaccination coverage over
time remained stable in our study population (average annual percent change 1.8%,
95% confidence interval [CI] -2.3% to 6.0%) versus significantly increasing by 2.8%
in NIS-Flu (95% CI 0.3% to 5.3%).
Conclusions: Vaccination coverage in our commercially insured pediatric population
was 51.4% lower than estimates from NIS-Flu during the same period, suggesting the
need for more accurate vaccination coverage surveillance, which will also be critical
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in future COVID-19 vaccination efforts.

Effective interventions are needed to

increase pediatric influenza vaccination rates to the Healthy People 2020 target of
70%.
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2.2 INTRODUCTION
The primary prevention and control of the influenza virus is through
vaccination (1) and the seasonal influenza vaccination program is one of the most
commonly utilized immunization programs in the United States (U.S.) (2).

The

influenza vaccine is safe and effective, prevents influenza-related complications (3, 4),
and it is particularly important in children as vaccination among children has been
shown to reduce influenza illness in older adults (5).
Although annual influenza vaccination is recommended for children, there is
continued hesitancy towards flu vaccines (6-8), and vaccination rates against influenza
remain below the Healthy People 2020 Goals of 70% for children aged 6 months
through 17 years of age (9). During the 2016-2017 influenza season, the National
Health Interview Survey (NHIS) and National Immunization Survey (NIS) vaccination
coverage among children was 49.7% (9) and 59.0% (10) respectively, and in 2014, a
Health Center Patient Survey estimated influenza vaccination coverage among
children to be 67.8% (11).
Actual annual influenza vaccine coverage in the United States, particularly
among children, is not well described as influenza vaccination coverage estimates are
ascertained from national surveys rather than vaccination records (12).

Other

countries, such as France, estimate influenza vaccine coverage based on the number of
influenza vaccines that were submitted for reimbursement (13). As such, estimates of
annual influenza vaccination coverage in the U.S. have important limitations due to
the nature of the survey design. Each year, the Centers for Disease Control and
Prevention (CDC) reports national estimates of pediatric vaccination coverage overall
37

and stratified by age group, gender, and state based on findings from the NIS-Flu (10,
12). The NIS-Flu collects data from October through the following June from all 50
states and the District of Columbia (D.C.) via national dual landline and cellular listassisted random-digit-dialed telephone survey of households (12). Response rates are
approximately 50.8% to 53.1% for landline phones, and 26.2% to 28.7% for cellular
phones (12). Influenza vaccination coverage is then estimated with Kaplan-Meier
survival analysis to determine cumulative vaccination coverage by state, estimated
from the state’s total monthly population by age (12).
Non-response bias may influence the accuracy of the estimates. In addition to
non-response bias, which can remain after weighting adjustments, this survey data is
also subject to recall bias (12). As a result of these limitations, it is recognized that
estimates from the NIS-Flu are “certainly” overestimated, since in previous years, the
estimated coverage exceeded the number of vaccines distributed by approximately 4 to
5 million in the 2009-2010 influenza season (12, 14).

A previous study using

Medicare fee-for-service administrative claims database found influenza vaccination
coverage estimates for the 2015-2016 influenza season to be 51% for adults 65 years
and older and 32% for adults under 65 years of age (15), whereas, the Behavioral Risk
Factor Surveillance System (BRFSS) estimates reported by the CDC were 63.4% for
adults 65 years and older and 36.3% for adults 18-64 years of age (16). Vaccination
coverage estimates from NIS-Flu have also been higher than estimates from the
National Health Interview Survey (NHIS) (10).
Therefore, the objective of this study was to quantify influenza vaccination
coverage from vaccine administration claims among a commercially insured pediatric
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population. Further we sought to compare coverage rates from our study population
with estimates from NIS-Flu, overall and by state, and to assess temporal trends in
overall coverage, and stratified by age group, sex, and geographic region.
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2.3 METHODS
This retrospective cohort study included pediatric patients less than (<) 18
years of age in Optum’s de-identified Clinformatics® Data Mart Database, a claims
data warehouse of commercially insured persons.

Time was assessed as annual

influenza seasons, from July 1 through June 30 of the following year (17), from 2010
to 2017. To be included in an influenza season, continuous enrollment was required
for the entire timeframe of each season. For example, to be included in the 2016-2017
season, children had to be continuously enrolled from July 1, 2016 through June 30,
2017. Age was calculated for each season, using the patient’s year of birth and year
from the beginning of the specific season.

For example, 2016 was used in the

calculation of age for the 2016-2017 influenza season.

Among children with

continuous enrollment each season, the proportion vaccinated during that season was
identified based on the presence of an influenza vaccination Current Procedural
Terminology, 4th Edition (CPT®-4) code, which can be found in Supplementary Table
1.
Only the initial influenza vaccination record during each season was included,
as it is recommended to be vaccinated once per season, with the exception of initial
influenza vaccine given to children 6 months to 8 years old, where two vaccines are
recommended in the first season (17). Patients with missing age, sex, or state were
excluded from the study. Coverage rates were calculated by age group, sex, and
geographic region (18).

In order to compare coverage rates from the Optum

Clinformatics® Data Mart Database with NIS-Flu, we included enrollees from all 50
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states and the District of Columbia and age was categorized as 6 months-4 years, 5-12
years, and 13-17 years (12). Vaccination coverage by state was also assessed (10).
Statistical Analysis
To compare influenza vaccination coverage from the claims database with
previous national estimates, pediatric influenza vaccination coverage data from the
NIS-Flu for the same time period was included (12). Student’s t-test was used to
compare pediatric influenza vaccination coverage between the study population and
NIS-Flu. For visual state-level comparisons between the study population and NISFlu, the 2016-2017 season was utilized, as it was the most recent available, and the
2017-2018 season from NIS-Flu was utilized, as it was the first season NIS began
reporting state-level pediatric vaccination coverage (10). All statistical analyses were
performed using SAS (version 9.4, SAS Institute Inc., Cary, NC).
Joinpoint regression (19) was utilized to assess trends in influenza vaccination
coverage over seven influenza vaccination seasons, from 2010 to 2017. Each season
was considered an interval and all intervals were equally weighted. Using permutation
tests, the trend data is fit into the simplest Joinpoint model and the average annual
percent changes (AAPC) in vaccination coverage was calculated and expressed as a
proportion of the population vaccinated overall, and stratified by age, sex, and region.
AAPCs and corresponding 95% confidence intervals were calculated using the
Joinpoint Regression Program, version 4.7.0.0 (National Cancer Institute, Bethesda,
MD). Statistical significance was defined as a p-value <0.05.
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2.4 RESULTS
In the study population of children from all 50 states and D.C., with per season
continuous enrollment in the de-identified Optum Clinformatics® Data Mart
Database, an average of 562,482 (± 32,961) children were vaccinated each season.
Average annual pediatric influenza vaccination coverage was 33.4% (± 2.4%; Table
1), ranging from 29.7% in the 2010-2011 season to a peak of 36.3% during the 20132014 season, where the predominant virus strain was influenza A (H1N1), and ending
at 34.1% in 2016-2017 season (Figure 1) (20). When compared to the same seven
influenza seasons, the estimated annual pediatric influenza vaccination coverage of
56.5% from the NIS-Flu differed significantly from our study population (p-value
<0.0001), starting at 51.0% in the 2010-2011 season, to a peak of 59.3% during the
2014-2015 and 2015-2016 seasons, and ending at 59.0% in 2016-2017 season (12),
resulting in a 51.4% difference between the commercially insured pediatric study
population and the NIS-Flu estimate.
Influenza vaccination coverage among children in our study remained stable
over the study period (AAPC 1.8%, 95% CI, -2.3% to 6.0%, p-value >0.05), while
NIS-Flu estimates showed a statistically significant increase in pediatric vaccination
coverage (AAPC 2.8%, 95% CI 0.3% to 5.3%, p-value <0.05; Table 1 and Figure 1).
This significant increase in pediatric vaccination coverage was observed in all age
groups in the NIS-Flu, while vaccination coverage remained relatively stable in all age
groups in the study population. The average annual percent change in vaccination
coverage was highest for the 13-17-year age group in the study population, at 6.0%
per year (95% CI, 0.0% to 12.5%, p-value >0.05), which was a similar trend to NIS42

Flu, though non-significant in the study population (NIS-Flu AAPC 6.6%, 95% CI,
2.8% to 10.5%, p-value <0.05).
In our study population, no significant temporal trends were observed in
pediatric influenza vaccination by sex or region (Table 1 and Figure 2). Average
annual influenza vaccination coverage among children was highest in the Northeast
(45.2%), followed by the Midwest (34.8%), South (31.3%), and lowest in the West
(30.3%).

The average annual percent change in pediatric influenza vaccination

coverage was highest in the South (AAPC 2.6%, 95% CI -1.1% to 6.4%), and lowest
in the Midwest (AAPC 1.0%, 95% CI -2.8% to 4.9%), however all were not
statistically significant. Average annual pediatric influenza vaccination coverage was
33.4% for girls and 33.3% for boys (p-value = 0.98) (Table 1). The average annual
percent change in pediatric influenza vaccination coverage was 1.8% per year (95%
CI, -2.1% to 5.7%) for girls and 1.7% per year (95% CI, -2.2% to 5.9%) for boys.
Among our commercially insured pediatric study population during the 20162017 influenza season, the highest state-level pediatric influenza vaccination coverage
was 52.6% in Rhode Island and the lowest was 14.1% in Alaska (Figure 3). Rhode
Island also had the highest estimated influenza vaccination coverage according to NISFlu during the 2017-2018 influenza season (10), however, with a higher estimated
vaccination rate of 76.2%. The average state-level difference in influenza vaccination
coverage between our study and NIS-Flu was 25.1%. Utah had the smallest difference
in influenza vaccination coverage estimates of 12.8% between our study and NIS-Flu
and New Mexico had the largest difference in estimates of 41.5%.
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2.5 DISCUSSION
Among a large national cohort of commercially insured children, average
pediatric influenza vaccination coverage was 33.4% per year, which is less than half of
the Healthy People 2020 target of 70% (9), and 51.4% lower than coverage estimates
of 56.5% from the NIS-Flu survey during the same time period (p-value <0.0001)
(12).

According to NIS-Flu, pediatric influenza vaccination coverage increased

significantly by 2.8% each year over the 7-year period, while in the Optum
Clinformatics® Data Mart, coverage increased non-significantly by 1.8%. Similar to
previous studies, this study found that vaccination coverage was highest among
younger children and decreased with increasing age (10, 12, 16, 21).
Pediatric influenza vaccination coverage rates in our study population were
consistently lower than the vaccination coverage estimates reported by NIS-Flu (10,
12), across age groups and states. NIS-Flu is subject to non-response bias from low
response rates among other biases related to the survey design, weighting, and
estimation (10, 12, 22-25). The large discrepancies between estimates from our study
population and the NIS-Flu reported estimates are likely attributable to the recognized
over-estimation of influenza vaccination coverage by NIS-Flu, as their estimates have
previously exceeded the number of seasonal influenza vaccines distributed (12, 14).
These observed differences between records of vaccine administrations in our study
population and survey responses from NIS-Flu suggest that survey data may not
accurately estimate vaccination coverage. In future research, it would be interesting to
see whether vaccination coverage from other publicly and privately insured children
reflect the vaccination coverage observed in our commercially insured pediatric
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population. Further, it may be informative to compare NIS-Flu estimates for adults,
also captured using survey data, to claims data from other insured adult populations.
The low pediatric influenza vaccination coverage rate observed in our study is
extremely concerning and interventions are critically needed to increase pediatric
influenza immunization in order to control future influenzas epidemics. Strategies that
have been shown to increase vaccination rates among children, such as decreasing
practice-related barriers and increasing access to vaccines, as well as patient/parent
education, recommendations, and reminders, need to be expanded (26). Children are
well-known for transmitting influenza throughout their homes and communities (27),
and vaccination among children has been shown to decrease influenza-related
hospitalizations in older adults (5). Although annual influenza vaccination is included
in the recommended immunization schedule for children by the Advisory Committee
on Immunization Practices (ACIP), influenza vaccination rates among children are
much lower than other childhood vaccines (28). This may be attributed to vaccine
hesitancy due to potential concerns about side effects, misconceptions regarding
immunizations being associated with autism, objections to the number of
immunizations administered in childhood, moral or religious concerns, lack of access,
and lack of information (28). Additionally, concerns regarding vaccine effectiveness,
which varies by season, are thought to contribute to increased influenza vaccine
hesitancy, compared with other vaccines (29).
Lower-than-expected pediatric influenza vaccination coverage is particularly
alarming during the current Coronavirus Disease 2019 (COVID-19) pandemic. The
influenza vaccine has been licensed in the United States since 1945 (30).
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The

influenza vaccine has been well-studied, with an excellent safety profile which is wellunderstood based on decades of scientific research and experience.

Conversely,

COVID-19 vaccines are new, along with the virus and presentation of illness
themselves (31).

COVID-19 vaccines have not been studied for decades, like

influenza, which may impact COVID-19 vaccination hesitancy among children and
parents.
These findings demonstrate an urgent public health need to improve influenza
vaccination uptake and better understand influenza vaccine hesitancy, as well as
COVID-19 vaccine hesitancy. Rates of influenza infection have decreased over the
2020-2021 influenza season compared to previous seasons (32), which can likely be
attributed to COVID-19 risk mitigation practices such as masking, handwashing,
social distancing, virtual learning, among other changes in health behaviors and
infection control practices (33).

As COVID-19 vaccinations are made widely

available, risk mitigation practices may wane, and the impacts of concurrent influenza
and COVID-19 outbreaks are not yet understood, highlighting the urgent need for the
development of effective interventions to increase influenza vaccination, as well as
COVID-19 vaccination in children. Herd immunity against COVID-19 can only be
created through widespread vaccination (6). If the low influenza vaccination coverage
rates observed in this study are representative of future COVID-19 vaccination
coverage rates, when COVID-19 vaccines become authorized for use in children,
addressing parents’ hesitancy towards vaccination will be “instrumental to achieving
herd immunity in the US” (34).
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With expectations that influenza and COVID-19 will both circulate
concurrently in the future and require annual vaccination to address changes in virus
variants, a combination quadrivalent seasonal influenza and COVID-19 vaccine from
Novovax, Inc using recombinant hemagglutinin (HA) nanoparticle technology is
currently in development (35). Tracking the differences in vaccination uptake from a
combination vaccine compared to individual vaccines may become an important
strategy to help increase vaccine uptake for both viruses.

Furthermore, greater

understanding of the origin around vaccine hesitancy, can be used to develop
strategies to inform such undecided individuals and in turn increase vaccination rates,
particularly for the influenza and COVID-19 vaccines (36).
Limitations
A claims database was utilized for this study and we measured influenza
vaccination coverage from influenza vaccination procedure code claims. Therefore,
influenza vaccinations that were not submitted for reimbursement, such as those
administered through free public health clinics which did not process the vaccination
through health insurance, were not captured. This underestimation is expected to be
low, assuming the majority of vaccine administrations are processed through health
insurance among a commercially insured pediatric population. However, we were
unable to obtain an accurate published estimate of this figure. It should also be noted
that the 5-12-year age group encompasses eight years, while the other age groups
encompass five or less years, however, these age groupings were used to easily
compare findings from our study population to NIS-Flu data. The population studied
was limited to pediatric patients from one commercially insured population in the
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United States with enrollees from all 50 states and D.C., and did not include pediatric
patients with Medicaid, which is estimated to include approximately 30 million
children nationally (37), or other private health plans. The proportion of children who
were vaccinated and included in the study population varied by state, as did the total
state pediatric population enrolled in the database. Therefore, estimates from our
study population are not state-wide estimates. Other variables which may influence
influenza vaccination coverage including socioeconomic status, and education (29),
comorbidities, religion, parent/family vaccination rates, geographic issues of access,
and parental perceptions of susceptibility to influenza virus and vaccine risk (38) were
not assessed.
A major limitation of our study was that race and ethnicity were not available
in our dataset, and therefore we were unable to assess trends in vaccination coverage
by race and ethnicity. Influenza vaccination coverage estimates by race from NIS-Flu
in 2017 were as follows 55.8% White, 55.4% Black, 61.7% Hispanic, 62.0% nonHispanic, 68.8% Asian, 53.8% American Indian or Alaska Native, and 57.3% other
races (10). We would expect the observed overestimation of NIS-Flu estimates for
other variables to hold true for race and ethnicities, although it is unclear as to whether
the overestimation is either more or less pronounced for specific races or ethnicities.

48

2.6 CONCLUSION
The primary and most cost-effective way to prevent influenza illness is through
vaccination (27), which has been licensed in the United States for over 75 years (30).
The vaccine is well-studied and has been proven to be safe and effective in countless
studies.

Despite the extensive experience with influenza vaccination in children,

annual vaccination coverage was found to be only 33.4% over seven influenza seasons
from 2010-2017 among a large national cohort of commercially insured children from
all 50 states and D.C. Vaccination coverage in the study population was 51.4% lower
than the average annual influenza vaccination coverage estimate of 56.5% (12)
reported by NIS-Flu from survey data, for the same period.
The significantly higher coverage rate reported by NIS-Flu suggests the need
for more accurate estimates of pediatric influenza vaccination coverage.

Newer

surveillance techniques, designed to accurately estimate influenza vaccination
coverage, may also have direct applications to the COVID-19 pandemic and future
pandemics with respect to vaccination coverage and distribution. Most importantly,
interventions are critically needed to increase pediatric influenza vaccination rates.
Similar efforts will be needed to ensure high utilization of pediatric COVID-19
vaccination, when authorized for children.
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2.8 TABLES AND FIGURES

Table 1. Trends in annual pediatric influenza vaccination coverage, Optum
Clinformatics® Data Mart and NIS-Flu
Patient characteristic

Average

Average annual

influenza vaccination

percent change

coverage, 2010-2017

(95% confidence
interval)

Overall
Optum Clinformatics® Data Mart

33.4%

1.8 (-2.3 – 6.0)

56.5%

2.8* (0.3 – 5.3)

52.6%

-0.0 (-1.8 – 1.8)

68.8%

1.6* (1.4 – 1.8)

33.2%

1.9 (-2.3 – 6.3)

58.9%

2.1* (0.4 – 3.9)

20.1%

6.0 (0.0 – 12.5)

42.8%

6.6* (2.8 – 10.5)

Female

33.4%

1.8 (-2.1 – 5.7)

Male

33.3%

1.7 (-2.2 – 5.9)

NIS-Flu
Age Group
Optum Clinformatics® Data Mart,
6 months to 4 years
NIS-Flu, 6 months to 4 years
Optum Clinformatics® Data Mart,
5 to 12 years
NIS-Flu, 5 to 12 years
Optum Clinformatics® Data Mart,
13 to 17 years
NIS-Flu, 13 to 17 years
Sex, Optum Clinformatics® Data Mart
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Region, Optum Clinformatics® Data Mart
Northeast1

45.1%

1.3 (-1.0 – 3.7)

Midwest2

34.8%

1.0 (-2.8 – 4.9)

South3

31.3%

2.6 (-1.1 – 6.4)

West4

30.3%

2.0 (-1.8 – 5.9)

NIS-Flu = National Immunization Survey-Flu
* P-value <0.05
Maine, New Hampshire, Vermont, Massachusetts, Rhode Island, Connecticut, New York,
New Jersey, Pennsylvania
2
Ohio, Indiana, Michigan, Illinois, Wisconsin, Missouri, Iowa, Minnesota, North Dakota,
South Dakota, Nebraska, Kansas
3
West Virginia, District of Columbia (DC), Virginia, North Carolina, Kentucky, Maryland,
Delaware, Tennessee, South Carolina, Georgia, Florida, Alabama, Mississippi, Arkansas,
Louisiana, Oklahoma, Texas
4
Montana, Wyoming, Colorado, Utah, Idaho, Nevada, Washington, Oregon, California,
Alaska, Hawaii, New Mexico, Arizona
1
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Figure 1. Annual pediatric influenza vaccination coverage by age group, Optum Clinformatics® Data Mart and NIS-Flu
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Solid line = Optum Clinformatics® Data Mart.
Dotted line = National Immunization Survey-Flu.
Note: 5-12 year age group and Overall lines are overlapping

Figure 2. Annual pediatric influenza vaccination coverage by region, Optum Clinformatics® Data Mart
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Northeast: Maine, New Hampshire, Vermont, Massachusetts, Rhode Island, Connecticut, New York, New Jersey, Pennsylvania
Midwest: Ohio, Indiana, Michigan, Illinois, Wisconsin, Missouri, Iowa, Minnesota, North Dakota, South Dakota, Nebraska, Kansas
South: West Virginia, District of Columbia (DC), Virginia, North Carolina, Kentucky, Maryland, Delaware, Tennessee, South Carolina, Georgia,
Florida, Alabama, Mississippi, Arkansas, Louisiana, Oklahoma, Texas
West: Montana, Wyoming, Colorado, Utah, Idaho, Nevada, Washington, Oregon, California, Alaska, Hawaii, New Mexico, Arizona

Figure 3. Annual pediatric influenza vaccination coverage by state, Optum Clinformatics® Data Mart and NIS-Flu
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NIS-Flu = National Immunization Survey-Flu.
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3.1 ABSTRACT
Background: Pediatricians’ offices are primary locations for pediatric influenza
vaccination. However, pharmacists are well-positioned as immunizers, particularly in
light of the COVID-19 pandemic and Public Readiness and Emergency Preparedness
(PREP) Act which has expanded the authority of pharmacists to vaccinate children.
Methods: We used the de-identified Optum Clinformatics® Data Mart database to
identify demographic and clinical predictors of pharmacist-administered pediatric
influenza vaccination compared with influenza vaccination in pediatricians’ offices.
Procedures codes for influenza vaccinations among children were captured for the
2016-2017 influenza season. Logistic regression was used to identify significant
predictors.
Results: We included 336,841 children receiving influenza vaccines by a pharmacist
(5.2%) or in pediatricians’ offices (94.8%). The following significant predictors were
identified: older age groups (13-17 years odds ratio [OR] 91.51, 5-12 years OR 35.41),
states allowing pharmacist-administered influenza vaccination at younger ages (no age
restrictions OR, 26.68, minimum age 2-4 years old OR, 33.76), influenza vaccination
outside of pediatricians’ offices in the previous year (pharmacist-administered OR,
22.18, convenience care OR 4.15, emergency care OR 1.69), geographic region (South
OR, 2.02, Midwest OR 1.60, and West OR 1.38), and routine health exam or followup in the prior 6-months (OR, 1.59).
Conclusions: The strongest drivers of pharmacist-administered pediatric influenza
vaccination were older age, more lenient minimum age restrictions, and previous
influenza vaccination in a pharmacy. Due to the COVID-19 pandemic, the PREP Act,
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and forthcoming pediatric COVID-19 vaccines for children, pharmacists may play a
greater role in pediatric vaccination resulting in sustained changes in pediatric
vaccination practices.
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3.2 INTRODUCTION
Historically, pediatric vaccination rates have been below the Healthy People
2020 goal of 70% [1] and increasing access to influenza vaccines is a leading strategy
to increase vaccination rates [2]. Pediatric vaccination often occurs in pediatrician’s
offices, with approximately 66.8% of all pediatric vaccinations taking place in a
doctor’s office during the 2017-2018 influenza season [3]. Beginning in the 1990s,
various states have passed laws allowing pharmacists to administer vaccines and by
2009, pharmacists were granted influenza vaccination authority in all states [4-6]. In
the United States, individual states govern regulatory mandates for pharmacistadministered vaccinations. A common regulation is a minimum age restriction for
pharmacist administration of influenza vaccination in children, which varies by state
[7-9].

Positive experiences with pharmacies are common [10], and 93% of the

population live within five miles of a pharmacy [11]. In addition, pharmacies are
found to be more accessible with more widespread locations, have more convenient
hours, and require less time than a pediatrician’s office visit [12, 13].
During the 2016-2017 influenza season, pediatric vaccination coverage
reported by the Centers for Disease Control and Prevention (CDC) using data from the
National Immunization Survey (NIS-Flu) was 59% [14], much lower than the Healthy
People 2020 target of 70% [1]. Additionally, older children have lower influenza
vaccination coverage, which has been consistently observed since 2010 [3, 15]. In the
2016-2017 influenza season, the NIS-Flu coverage estimate for the 13-17 year old age
group was 48.8% [14]. Children between the ages 5-17 have previously been shown
to be highly susceptible to the influenza virus as well as highly involved with virus
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transmission to others and vaccinating this group can reduce the impact of influenza
within the community [16]. Based on these findings and critical need, increased
utilization of pharmacist-administered influenza vaccination can lead to increases in
overall vaccination rates and subsequently reduce the transmission of the influenza
virus.
Differences among children vaccinated by a pharmacist compared with
children vaccinated in a pediatrician’s office are not known. Understanding drivers
and barriers to pharmacist-administered vaccination allows identification of target
populations for educational interventions about pediatric influenza vaccination,
including pharmacist vaccination of children. Therefore, the purpose of our study was
to determine demographic and clinical characteristics predictive of pharmacistadministered influenza vaccination among children when compared with influenza
vaccination in pediatrician’s offices.
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3.3 METHODS
The Optum Clinformatics® Data Mart Database, a claims data warehouse of
commercially insured persons, was used to conduct this study. The study population
included pediatric patients, less than (<) 18 years old, who obtained an influenza
vaccine between July 1, 2016 to June 30, 2017 as identified from Current Procedural
Terminology (CPT) codes in Supplemental Table 1.

Patients were continuously

enrolled for the entire influenza season and the preceding year (July 1, 2015 to June
30, 2016). Duplicate vaccinations within the study period were removed as it is
recommended to be vaccinated once per season, except for initial vaccination [17].
For the purposes of this study, the initial vaccination was considered. The study
population was limited to children residing in any of the 50 states or the District of
Columbia. Children vaccinated by pharmacists or in pediatricians’ office, including
primary care and family medicine offices, were selected for inclusion. The study
population identification flowchart can be found in Figure 1.
We developed a list of potential predictors a priori, which included
demographic characteristics (age, sex, geographic region defined by the U.S. Census
Bureau [18]) and clinical characteristics based on International Classification of
Diseases (ICD-10) codes in the 6 months preceding administration of the influenza
vaccine. Clinical characteristics included the most common pediatric health conditions
and healthcare utilization (Supplemental Table 2) and other less common
comorbidities which increase the risk of severe influenza illness (Supplemental Table
3). We also assessed prior influenza season vaccination status and location and age
restrictions of state-level pharmacist-authorization models.
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Statistical Analysis
We compared the distribution of demographic and clinical characteristics
among children vaccinated by pharmacists and children vaccinated in pediatricians’
offices. Age was assessed as a categorical variable; 6 months to 4 years old, 5 to 12
years old, and 13 to 17 years old [14]. Using statistical software for all analyses (SAS,
version 9.4, SAS Institute Inc., Cary, NC), the non-parametric Wilcoxon Rank Sum
Scores was used to evaluate differences in median age. Fisher’s exact tests and chisquare tests were used to evaluate differences in categorical variables. Statistical
significance was assessed using a 2-sided test, with significance being ≤0.05.
Logistic regression was utilized to identify predictors of pharmacistadministered pediatric influenza vaccination. Variables with a likelihood ratio p-value
of less than 0.2 from the univariate analysis were selected for inclusion in the initial,
full multivariable model [19].

Absence of multicollinearity of this model was

confirmed. Stepwise, backward elimination [19] was utilized to remove variables that
were not significant (p-value >0.05 from likelihood ratio testing and Wald p-values),
until all the variables were significant in the final model (p-value ≤ 0.05) [19]. The
Hosmer and Lemeshow goodness of fit test was used to assess model fit [19].
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3.4 RESULTS
We identified 336,841 children with influenza vaccinations in the 2016-2017
season, with 17,535 (5.2%) children vaccinated by pharmacists and 319,306 (94.8%)
vaccinated in a pediatrician’s office.

A number of significant differences were

observed between the groups in terms of demographic and clinical characteristics
(Table 1). Pharmacist-administered influenza vaccination was highest in those 13-17
years of age (57.6% versus 21.1% in the pediatricians’ office, p<0.0001). Among
both groups, there were more males than females (50.3% in a pharmacy versus 51.3%
in a pediatrician’s office, p=0.0093). Geographic differences were observed between
groups, the most noticeable being in the Northeast region where pharmacistadministered influenza vaccination was the lowest (3.3% versus 14.0% in a
pediatrician’s office, p<0.0001).

Previous year influenza vaccination was higher

among children receiving their vaccination in a pediatrician’s office (70.4%)
compared with pharmacist-administration (67.4%, p<0.0001).

In the pharmacist-

administered group, 52.1% of those vaccinated in the previous year had used a
pharmacy versus 1.3% in the pediatricians’ office group (p<0.001).

Lastly,

pharmacist-administered vaccination was more common in states with no minimum
age restrictions (36.5%, versus 25.2% in a pediatrician’s office, p<0.0001).
Unadjusted and adjusted odds ratios and corresponding 95% confidence
intervals are reported in Table 2. Our final multivariable logistic regression model
included five statistically significant predictors of pharmacist-administered pediatric
influenza vaccination and eight variables significantly associated with pediatricians’
office vaccination (Table 2, Figure 2).
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Predictors of pharmacy-based influenza vaccination included age group, state
restrictions, previous vaccination setting, geographic region, and recent health
examination or follow-up.

Older age was predictive of pharmacist-administered

vaccination with an odds ratio (OR) of 91.51 for the 13-17-year age group (95%
confidence interval [CI] 73.49-113.94; reference group 6 months to 4 years) and OR
of 35.41 for the 5-12 year age group (95% CI, 28.45-44.07).

States permitting

pharmacist-administered influenza vaccination at younger ages were also predictive of
pharmacist-administered pediatric influenza vaccination, including states with no age
restrictions (OR, 26.68; 95% CI, 21.31-33.41; reference group did not allow
pharmacist-administered pediatric influenza vaccination in children under 18 years
old), and states with minimum age restrictions between 2 and 4 years old (OR, 33.76;
95% CI, 26.466-43.07), minimum age restrictions between 5 and 12 years old and any
age with prescription (OR, 20.93; 95% CI, 16.75-26.16), minimum age restrictions
between 5 and 12 years old (OR, 15.54; 95% CI, 12.43-19.43),

minimum age

restrictions between 13 and 17 years old and any age with prescription (OR, 13.62;
95% CI, 10.67-17.39), and minimum age restrictions between 13 and 17 years old
(OR, 8.95; 95% CI, 6.93-11.55).
Previous year vaccination setting was another predictor of pharmacistadministered vaccination, including previous pharmacist-administered influenza
vaccination (OR, 22.18; 95% CI, 21.02-23.41; reference group was unvaccinated in
the previous year), and previous year vaccination in a convenience care (OR, 4.15;
95% CI, 3.76-7.58), emergency care setting (OR, 1.69; 95% CI, 1.33-2.14), or other
setting (OR, 1.13; 95% CI, 1.01-1.25). Residence in the South (OR, 2.02; 95% CI,
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1.82-2.25; reference Northeast), Midwest (OR, 1.60; 95% CI, 1.45-1.77), and West
(OR, 1.38; 95% CI, 1.24-1.55) were predictive of pharmacist-administered pediatric
influenza vaccination, as was having a routine health examination or follow-up
appointment in the 6-month baseline period (OR, 1.59; 95% CI, 1.53-1.65).
Alternatively, the following were significant predictors of pediatricians’ office
pediatric influenza vaccination: previous diagnosis of acute upper respiratory infection
(OR, 0.91; 95% CI, 0.83-0.99); attention-deficit/hyperactivity disorder (ADHD) (OR,
0.90; 95% CI, 0.83-0.98); Streptococcal sore throat (OR, 0.87; 95% CI, 0.79-0.96);
cough (OR, 0.85; 95% CI, 0.77-0.94); fever (OR, 0.85; 95% CI, 0.76-0.95); obesity
(OR, 0.84; 95% CI, 0.73-0.98); otitis media (OR, 0.79; 95% CI, 0.70-0.89); and
severe developmental delay (OR, 0.66; 95% CI, 0.53-0.83).
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3.5 DISCUSSION
To our knowledge, this study is the first to identify predictors of pharmacistadministered pediatric influenza vaccination among a commercially insured pediatric
population. Pharmacist-administered influenza vaccination was associated with older
age, less restrictive minimum age requirements, previous vaccination outside of the
pediatrician’s office, region, and previous routine health examination or follow-up
visit.
From these results, age and minimum age restrictions were the strongest
drivers of pharmacist-administered influenza vaccination. Children between the ages
of 13 and 17 were 91 times as likely to receive an influenza vaccine administered by a
pharmacist than younger children aged 6 months to 4 years. Previous research has
identified parent willingness as a facilitator of pharmacist-administered pediatric
vaccination, specifically in older children. In a previous study conducted via online
surveys among parents of 11-17 years old in 2014 and 2015, 62% of parents were
willing to have a pharmacist administer the influenza vaccine to their child, which was
higher than any other vaccine evaluated (combination tetanus, diphtheria, pertussis
[Tdap] booster, 41%; meningococcal vaccine, 33%; human papillomavirus [HPV],
29%) [20]. Other studies have evaluated adolescent HPV vaccine administration by
pharmacists [12, 20-22], which found pharmacies to be more accessible, have more
convenient hours, and require less time than a pediatrician’s office [12].

Parent

willingness to vaccinate in a pharmacy was also found to be higher when they
believed that pharmacists were skilled at vaccine administration, when parents thought
vaccines were important, and when parents thought pharmacist-administered
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vaccination would expand healthcare opportunities for children [20]. More lenient
state-level minimum age requirements significantly increased the likelihood of
influenza vaccination by a pharmacist. As the minimum age at which state laws
allowed children to be vaccinated by a pharmacist decreased, the odds of pharmacistadministered pediatric influenza vaccination increased in a dose-response fashion
(Figure 2) as compared with the reference group of states which do not allow
pharmacist-administered pediatric influenza vaccination. For example, children in
states with no age restrictions were 27 times as likely to receive the influenza vaccine
from a pharmacist, whereas patients in states with minimum age restrictions between
13 and 17 years were only 9 times more likely to be vaccinated by a pharmacist. More
strict regulations, particularly state-governed minimum age restrictions, act as a barrier
to pharmacist-administered pediatric influenza vaccination by limiting access to
mainly pediatricians’ offices, rather than expanding access through community
pharmacies.

A main goal of pharmacist-administered influenza vaccination is to

expand access to vaccines, however, such restrictions are hindering these efforts.
Some concerns regarding pharmacist-administered pediatric vaccination that may
result in such limitations is that the visit with the pharmacist for a vaccine may replace
a child’s wellness visit with their pediatrician, where the pediatrician provides
essential care that a pharmacist cannot, such as by preventative screening, performing
routine exams, counseling, answering questions, and establishing trusting relationships
[23]. The findings from this study are somewhat inconsistent with the idea above, as
children who are vaccinated in a pharmacy were 59% more likely to have a routine
exam or follow up in the previous 6 months compared to children vaccinated by their
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pediatrician.

For a more complete understanding, children vaccinated within a

pharmacy would need to be followed for a period of time after vaccination to
determine if there are significant differences in routine pediatric visits when compared
to children vaccinated in a pediatrician’s office.
Some states allow pharmacist-administered pediatric influenza vaccination in
additional age groups when a physician prescription is obtained.

This form of

expanded access for additional age groups via physician prescrption increased the
likelihood of pharmacist-administered pediatric influenza vaccination. In both the 512-year old age group and the 13-17-year old age group, allowing pharmacists to
vaccinate children against influenza via physician prescription increased the likelihood
of pharmacist-administered vaccination by 500%.
Previous vaccination in settings other than the pediatricians’ office,
particularly pharmacist-administered pediatric influenza vaccination, was associated
with subsequent pharmacist-administered pediatric influenza vaccination. Children
were 22 times as likely to receive the influenza vaccine from a pharmacist if they had
done so in the year prior. The increased likelihood of repeat utilization of pharmacists
as vaccinators was also observed in a study conducted among Canadian adults during
the 2013-2014 and 2015-2016 influenza seasons [24]. Vaccination in a pharmacy
provides greater access to vaccination through increased convenience and efficiency
[12], and commonly, patients find their experiences with a pharmacy positive [10].
These positive experiences within healthcare have been shown to be facilitators of
continued healthcare utilization. Previous studies have found that parents were more
willing to bring their children to chain/clinic pharmacies and whether they had
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previous positive experience with their pharmacy and knew their pharmacist(s)
moderately well [21].
Though individual states govern regulatory mandates for pharmacistadministered vaccinations, pharmacists were granted expanded vaccination authority
to administer any FDA authorized vaccine to children aged 3 to 18 under the “Third
Amendment to Declaration Under the Public Readiness and Emergency Preparedness
Act for Medical Countermeasures Against COVID–19” (PREP Act) released in
August 2020 [25] for the duration of the Coronavirus Disease 2019 (COVID-19)
pandemic.

The United States Health and Human Services Department (HHS)

recognized pharmacists were well-positioned to expand access to all childhood
vaccinations to combat the alarming decline in routine pediatric vaccines observed
during the onset of the pandemic [25, 26].
This amendment is recent and the effectiveness of these changes, specifically
utilization of pharmacist-administered pediatric vaccination, is not yet known. Other
unknowns include parental awareness of this expanded access to vaccination in
community pharmacies in states which had older minimum age restrictions, the
duration of this expanded access, and the influence of the PREP Act on future
vaccination practices. According to our study, previous influenza vaccination by a
pharmacist was a strong predictor of subsequent influenza vaccination. This has
important implications if pharmacists become the primary administrators of COVID19 vaccines for children and/or if pharmacists become utilized more frequently for
typical childhood vaccines.

A first experience utilizing pharmacist-administered

pediatric vaccination of any kind while it is currently allowed in all states may drive
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continued utilization in that setting.

Because of this expansion in access to

vaccination due to the PREP Act, it will be important to evaluate, in future research,
the uptake of pharmacist-administered vaccination for influenza and all pediatric
vaccinations, including COVID-19 vaccines, when compared to pediatricians’ offices,
and determine whether the utilization changes observed are temporary changes or
sustained changes that increase pharmacy vaccination among children.
Children in regions outside of the Northeast were also more likely to be
vaccinated against influenza by a pharmacist. Historically, the Northeast region of the
United States, categorized by the U.S. Census Bureau [18], has the highest vaccination
rates in the country [27, 28]. However, from our analysis, children living in the South
were 2 times more likely to be vaccinated by a pharmacist when compared to the
Northeast. Aside from West Virginia and Florida, all other states in the South allow
pharmacist-administered pediatric influenza vaccination of various age limitations,
compared to the Northeast where pharmacists can administer the influenza vaccine
only to adults 18 years of age and older in Vermont, Massachusetts, Connecticut, and
New York [7]. It is possible that in this region of the country, pharmacies are much
more accessible than pediatrician’s offices in terms of number of pharmacies and
proximity to patients. Patients may utilize pharmacies more for reasons outside of
vaccination or there may be more awareness of pharmacist-administered pediatric
influenza vaccination among children and their families in this region as well. These
regional differences in influenza vaccination rates may be a sign of regional
differences that can be expected of COVID-19 vaccination rates for adults and
children, when available [27, 28]. Pharmacists are well positioned to administer
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COVID-19 vaccines, and as part of the Federal Retail Pharmacy Program for COVID19 Vaccination, have distributed nearly 94 million doses of COVID-19 vaccine at the
time this manuscript was authored [29].
Factors associated with vaccination in the traditional pediatricians’ office
setting were pre-existing conditions, including obesity, severe developmental delay,
ADHD, and infectious conditions, which require more frequent pediatricians’ office
visits, and therefore vaccinating within that setting may be more convenient for
parents and caregivers. Similarly, pre-existing conditions of diabetes, hypertension,
chronic obstructive pulmonary disorder, asthma, congestive heart failure, and acute
myocardial infarction among adults were found to be predictors of vaccination in a
physician’s office [24].

Obesity and developmental delay are associated with

increased risk of severe influenza infection and complications [30, 31], and therefore
may prompt reminders for influenza vaccination scheduling at those visits. Healthy
children without these conditions may only be seen for their annual check-up. If that
visit does not coincide with the height of the influenza vaccination season, families
may face barriers in scheduling a separate visit solely for the influenza vaccine, such
as time away from work for parents/caregivers and time away from school for
children.

At annual visits, physicians’ offices could provide a list of available

providers of pediatric influenza vaccination, including area pharmacies, to encourage
vaccination in whichever setting is most comfortable and convenient for each family.
Aside from age, age restrictions, and parent willingness, low pharmacistadministered influenza vaccination may be attributed to lack of awareness of
pharmacist vaccination as an option for their children [20, 32].
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Variability in

immunization delivery programs and workflows across different pharmacies can limit
the receptivity of pharmacist-administered influenza vaccination by patients,
caregivers, and pediatricians [33]. In addition, patients, caregivers, and physicians
may have concerns that vaccination outside of the pediatricians’ office or outside of
the pediatricians’ office health system may result in inaccurate or incomplete
vaccination records and documentation due to limited access to electronic medical
records and/or immunization information systems (IIS) by pharmacists [33].
Parent willingness to vaccinate their children against influenza from any
provider has also been associated with their child having had a previous influenza
vaccine, other family members regularly vaccinated against influenza, and perceived
safety and lack of side effects, determined from a survey study in 2011 [34]. Other
factors that can influence influenza vaccination or act as barriers to vaccination are
parental perceptions of susceptibility to influenza virus and vaccine risk [35],
unhealthy lifestyles, lack in access to care, socioeconomic status, and education [36].
Commonly reported reasons for parents and/or caregivers to not vaccinate their
children include lack of awareness of influenza vaccine recommendations and fear of
side effects [37]. Hesitancy toward vaccinations is also an increasing trend [13, 33,
38].

However, pharmacists can play an essential role in educating patients and

caregivers about the benefits of vaccination and correcting any misconceptions they
may have [13, 33], which has been shown to increase vaccination rates in adults [13].
Limitations
The study population was limited to pediatric patients from a single
commercially insured population within the U.S. and does not include pediatric
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patients with Medicaid, which is estimated to include approximately 30 million
children [39]. The proportion of children who were enrolled in the database varied by
state, which includes number of enrollees and differences in demographic and clinical
characteristics, which may attribute to differences in vaccination by region. Our study
is limited to the accuracy and consistency of coding in the claims database for
influenza vaccination claims, categorization of provider setting, and for claims of the
clinical comorbidities of interest. Typically, nurses or nurse practitioners administer
vaccines in the pediatric primary care setting, however there were several provider
category codes for nurse/nurse practitioner that do not specify an additional
description of primary care or pediatricians’ office and were therefore not included in
this study. This has the potential to reduce the number of influenza immunizations
included in the pediatricians’ office setting. Only the first influenza vaccine in each
season was included and it is possible a different provider setting was used in cases
where children received a second vaccine. In our study population, several
comorbidities evaluated had very low frequencies and may be significant if the
database was larger.

Lastly, we evaluated patient demographics and clinical

characteristics available from the claims database, and certain potential predictors,
such as race, are not available from the database and therefore could not be captured.
A similar study carried out using a different database that includes race could be used
to determine if race is predictive of pharmacist-administered pediatric influenza
vaccination.
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3.6 CONCLUSION
We found the utilization of pharmacist-administered pediatric influenza
vaccination in our study to be low compared to vaccination within a pediatrician’s
office and compared to pharmacist-administered adult influenza vaccination. The
strongest drivers of pharmacist-administered influenza vaccination were older age,
less restrictive minimum age requirements, and previous vaccination in a pharmacy.
Current minimum age restrictions have been shown to act as barrier to pharmacistadministered pediatric influenza vaccination, however, the current PREP Act overrides
any state governed minimum age restrictions, and pharmacists have been granted
authority to administer any FDA authorized vaccine to children 3 years of age and
older in all states [25].

Pharmacists will play an important role in increasing

vaccination rates among children for influenza and all pediatric vaccines, including
COVID-19 vaccines when they are authorized for children. Additionally, previous
vaccination in a pharmacy was a driver of pharmacist-administered pediatric influenza
vaccination.

Considering these two major findings, more children, particularly

younger children, may be utilizing pharmacists more for any vaccination for the
duration of the PREP Act, which has been shown to drive continued utilization in that
setting. It will be important to study whether the utilization changes are temporary
changes or sustained changes in the future.
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3.8 TABLES AND FIGURES
Table 1. Baseline characteristics of influenza vaccinated children
Pharmacist-

Pediatricians’

administered

Office

n = 17,535
5.20%

n = 319,306
94.80%

P-value

Age group
6 months to 4 years

82 (0.5%)

91,421 (28.6%)

5 to 12 years

7,346 (41.9%)

160,451 (50.3%)

13 to 17 years

10,107 (57.6%)

67,434 (21.1%)

Female

8,723 (49.8%)

155,623 (48.7%)

Male

8,812 (50.3%)

163,683 (51.3%)

Midwest

4,769 (27.2%)

91,326 (28.6%)

Northeast

570 (3.25%)

44,808 (14.0%)

South

7,508 (42.8%)

118,873 (37.2%)

West

4,688 (26.7%)

64,299 (20.1%)

No

5,715 (32.6%)

94,456 (29.6%)

Yes

11,820 (67.4%)

224,850 (70.4%)

Pediatricians’ office

4,575 (38.7%)

211,794 (94.2%)

Pharmacist-administered

6,159 (52.1%)

2,842 (1.3%)

<0.0001

Sex
0.0093

Region

<0.0001

Previous year vaccination
<0.0001

Previous year vaccination setting

84

<0.0001

Convenience care

608 (5.1%)

2,473 (1.1%)

Emergency care

81 (0.7%)

926 (0.4%)

Other settings

397 (3.4%)

6,815 (3.0%)

State Pharmacist Authorization Model, Age Restrictions
No age restriction

6,406 (36.5%)

80,384 (25.2%)

Minimum 2-4 years old

813 (4.6%)

8,158 (2.6%)

5,600 (31.9%)

76,957 (24.1%)

3,863 (22.0%)

93,508 (29.3%)

479 (2.7%)

9,287 (2.9%)

Minimum 13-17 years old1

292 (1.7%)

8,943 (2.8%)

Minimum 18 years old

82 (0.5%)

420,699 (13.2%)

Minimum 5-12 years old and any
age with physician prescription
Minimum 5-12 years old
Minimum 13-17 years and any
age with physician prescription

<0.0001

Healthcare Utilization and Common Pediatric
Conditions
Abdominal pain

343 (2.0%)

5,163 (1.6%)

Acute pharyngitis

1,587 (9.1%)

35,420 (11.1%)

<0.0001

Acute upper respiratory infection

822 (4.7%)

29,960 (9.4%)

<0.0001

Allergic rhinitis

1,230 (7.0%)

18,221 (5.7%)

<0.0001

840 (4.8%)

11,105 (3.5%)

<0.0001

Bronchitis

168 (1.0%)

3,822 (1.2%)

0.0044

Conjunctivitis

96 (0.6%)

2,335 (0.7%)

0.0051

Attention-deficit/hyperactivity
disorder

85

0.0006

Constipation, unspecified

187 (1.1%)

5,016 (1.6%)

<0.0001

Cough

589 (3.4%)

19,336 (6.1%)

<0.0001

Dermatitis

96 (0.6%)

1,491 (0.5%)

0.1295

Esophageal reflux

137 (0.8%)

2,428 (0.8%)

0.7566

Fever

442 (2.5%)

21,639 (6.8%)

<0.0001

Gastroenteritis/colitis

101 (0.6%)

2,589 (0.8%)

0.0007

Influenza

68 (0.4%)

1,768 (0.6%)

0.0037

Otitis media

391 (2.2%)

20,662 (6.5%)

<0.0001

Pneumonia

107 (0.6%)

3,916 (1.2%)

<0.0001

Prophylactic vaccination

3,196 (18.2%)

51,915 (16.3%)

<0.0001

6,766 (38.6%)

108,547 (34.0%)

<0.0001

Sinusitis

176 (1.0%)

2,928 (0.9%)

0.2420

Streptococcal sore throat

541 (3.1%)

15,234 (4.8%)

<0.0001

Urinary tract infection, cystitis

154 (0.9%)

2,959 (0.9%)

0.5139

Viral diseases

220 (1.3%)

9,703 (3.0%)

<0.0001

Routine child health exam/followup

Other Less Common Pediatric Conditions
Blood disorders
Sickle cell anemia

5 (0.0%)

68 (0.0%)

0.5272

Hemoglobinopathy

4 (0.0%)

27 (0.0%)

0.0755*

Thalassemia major

0 (0.0%)

21 (0.0%)

0.6247*

1 (0.0%)

9 (0.0%)

0.4141*

Cardiac disease
Atherosclerotic heart disease
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Congenital heart disease

8 (0.0%)

207 (0.1%)

0.3269

Coronary artery disease

0 (0.0%)

3 (0.0%)

Intellectual disability

15 (0.1%)

233 (0.1%)

Severe developmental delay

93 (0.5%)

6,009 (1.9%)

<0.0001

Spinal cord injury

3 (0.0%)

99 (0.0%)

0.4980*

4 (0.0%)

1.0000*

1.0000*

Cognitive disorders
0.5501

Hepatic conditions
Chronic liver disease with cirrhosis 0 (0.0%)
Immunocompromised conditions
HIV/AIDS

1 (0.0%)

10 (0.0%)

0.4446*

Cancer

31 (0.2%)

350 (0.1%)

0.0100

Chemotherapy

1 (0.0%)

42 (0.0%)

0.7266*

Chronic corticosteroid therapy

4 (0.0%)

66 (0.0%)

0.7851*

Diabetes (Type 1)

97 (0.6%)

827 (0.3%)

<0.0001

Diabetes (Type 2)

16 (0.1%)

179 (0.1%)

0.0593

Cerebral palsy

25 (0.1%)

525 (0.2%)

0.4854

Muscular dystrophy

1 (0.0%)

60 (0.0%)

0.3778*

Neuromuscular disease

3 (0.0%)

88 (0.0%)

0.6334*

Epilepsy

0 (0.0%)

11 (0.0%)

1.0000*

Obesity

248 (1.4%)

3,262 (1.0%)

<0.0001

Renal disease

1 (0.0%)

67 (0.0%)

0.2672*

Metabolic/Endocrine conditions

Neurologic conditions

87

Respiratory disease
Asthma

1,006 (5.7%)

15,635 (4.9%)

<0.0001

Chronic lung disease

0 (0.0%)

17 (0.0%)

1.0000*

71 (0.4%)

1,477 (0.5%)

0.2717

Cystic fibrosis

9 (0.1%)

76 (0.0%)

0.0255

Pediatric emphysema

0 (0.0%)

13 (0.0%)

1.0000*

Chronic obstructive pulmonary
disease

*Fishers exact test was used due to low incidence of condition
Note: Healthcare utilization, common pediatric conditions, and pediatric comorbidities were
assessed in 6-month period prior to vaccination.
Northeast: Maine, New Hampshire, Vermont, Massachusetts, Rhode Island, Connecticut,
New York, New Jersey, Pennsylvania
Midwest: Ohio, Indiana, Michigan, Illinois, Wisconsin, Missouri, Iowa, Minnesota, North
Dakota, South Dakota, Nebraska, Kansas
South: West Virginia, District of Columbia (DC), Virginia, North Carolina, Kentucky,
Maryland, Delaware, Tennessee, South Carolina, Georgia, Florida, Alabama, Mississippi,
Arkansas, Louisiana, Oklahoma, Texas
West: Montana, Wyoming, Colorado, Utah, Idaho, Nevada, Washington, Oregon, California,
Alaska, Hawaii, New Mexico, Arizona
1
Includes Hawaii, where a prescription is required for pharmacist-administered influenza
vaccination.
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Table 2. Predictors of pharmacist-administered pediatric influenza vaccination
Unadjusted Odd
Ratios (95%
Confidence Interval)

Adjusted Odd
Ratios (95%
Confidence
Interval)*

Age Group
6 months to 4 years

Ref

Ref

5 to 12 years

51.04 (41.05-63.46)

35.41 (28.45-44.07)

13 to 17 years

167.10 (134.43-207.70)

91.51 (73.49-113.94)

Ref

-

1.04 (1.01-1.07)

-

Northeast

Ref

Ref

Midwest

4.11 (3.76-4.48)

1.60 (1.45-1.77)

South

4.97 (4.56-5.41)

2.02 (1.82-2.25)

West

5.73 (5.25-6.26)

1.38 (1.24-1.55)

No

Ref

-

Yes

0.87 (0.84-0.90)

-

Ref

Ref

0.36 (0.34-0.37)

0.51 (0.49-0.53)

35.82 (34.01-37.72)

22.18 (21.02-23.41)

Sex
Male
Female
Region

Previous Year Vaccination

Previous Year Vaccination Setting
Not previously vaccinated
Pediatricians’ Office
Pharmacist-administered
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Convenience Care

4.06 (3.70-4.46)

4.15 (3.76-4.58)

Emergency Care

1.45 (1.15-1.82)

1.69 (1.33-2.14)

Other Settings

0.96 (0.87-1.07)

1.13 (1.01-1.25)

State Pharmacist Authorization Model, Age Restrictions
Does not allow,

Ref

Ref

No age restriction

40.88 (32.87-50.85)

26.68 (21.31-33.41)

Minimum 2-4 years old

51.12 (40.69-64.24)

33.76 (26.46-43.07)

37.33 (30.01-46.44)

20.93 (16.75-26.16)

21.19 (17.02-26.38)

15.54 (12.43-19.43)

26.46 (20.91-33.48)

13.62 (10.67-17.39)

16.75 (13.10-21.42)

8.95 (6.93-11.55)

Minimum 18 years old

Minimum 5-12 years old
and any age w/ Rx
Minimum 5-12 years old
Minimum 13-17 years old
and any age w/ Rx
Minimum 13-17 years old1

Healthcare Utilization and Common Pediatric Conditions
Abdominal pain

1.21 (1.09-1.36)

-

Acute pharyngitis

0.80 (0.76-0.84)

-

Acute upper respiratory infection

0.48 (0.44-0.51)

0.91 (0.83-0.99)

Allergic Rhinitis

1.25 (1.17-1.32)

-

1.40 (1.30-1.50)

0.90 (0.83-0.98)

Bronchitis

0.80 (0.68-0.93)

-

Conjunctivitis

0.75 (0.61-0.92)

-

Attention-deficit/hyperactivity
disorder
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Constipation

0.68 (0.58-0.78)

-

Cough

0.54 (0.50-0.59)

0.85 (0.77-0.94)

Dermatitis

1.17 (0.95-1.44)

-

Fever

0.36 (0.32-0.39)

0.85 (0.76-0.95)

Gastroenteritis/colitis

0.71 (0.58-0.87)

-

Influenza

0.70 (0.55-0.89)

-

Otitis media

0.33 (0.30-0.37)

0.79 (0.70-0.89)

Pneumonia

0.50 (0.41-0.60)

-

Prophylactic vaccination

1.15 (1.10-1.19)

-

1.22 (1.18-1.26)

1.59 (1.53-1.65)

Streptococcal sore throat

0.64 (0.58-0.69)

0.87 (0.79-0.96)

Viral diseases

0.41 (0.36-0.46)

-

Routine child health
examination/follow-up

Other Less Common Pediatric Conditions
Blood disorders
Hemoglobinopathy

2.71 (0.95-7.73)

-

0.28 (0.23-0.34)

0.66 (0.53-0.83)

1.61 (1.12-2.33)

-

Diabetes (Type 1)

2.14 (1.74-2.65)

-

Diabetes (Type 2)

1.64 (0.98-2.73)

-

Cognitive disorders
Severe developmental delay
Immunocompromised conditions
Cancer
Metabolic/Endocrine conditions
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Neurologic conditions
Muscular Dystrophy

0.31 (0.04-2.19)

-

Obesity

1.39 (1.22-1.59)

0.84 (0.73-0.98)

Renal Disease

0.27 (0.04-1.96)

-

Asthma

1.18 (1.11-1.26)

-

Cystic fibrosis

2.16 (1.08-4.31)

-

Respiratory disease

Rx = Prescription
Note: Healthcare utilization, common pediatric conditions, and pediatric comorbidities were
assessed in 6-month period prior to vaccination.
Northeast: Maine, New Hampshire, Vermont, Massachusetts, Rhode Island, Connecticut,
New York, New Jersey, Pennsylvania
Midwest: Ohio, Indiana, Michigan, Illinois, Wisconsin, Missouri, Iowa, Minnesota, North
Dakota, South Dakota, Nebraska, Kansas
South: West Virginia, District of Columbia (DC), Virginia, North Carolina, Kentucky,
Maryland, Delaware, Tennessee, South Carolina, Georgia, Florida, Alabama, Mississippi,
Arkansas, Louisiana, Oklahoma, Texas
West: Montana, Wyoming, Colorado, Utah, Idaho, Nevada, Washington, Oregon, California,
Alaska, Hawaii, New Mexico, Arizona
1
Includes Hawaii, where a prescription is required for pharmacist-administered influenza
vaccination.

92

Identification

Figure 1. Flowchart of inclusion and exclusion criteria
Pediatric influenza vaccinations
from July 1, 2016 – June 30, 2017
(n = 866,483)

Continuous enrollment from
July 1, 2015 to June 30, 2017
(n = 382,282)

Eligibility

Initial pediatric
influenza vaccinations
(n = 376,770)

Duplicate pediatric influenza
vaccinations excluded
(n = 5,512)

Unknown sex (n= 2) and
state (n=690) and Puerto
Rico (n=4) excluded

Non-missing
sex and state
(n = 376,074)

Convenience care (n=9,542),
emergency care (n=3,286),
and other settings (n = 26,405)
excluded

Included

Vaccination setting:
pediatricians’ office or
pharmacist-administered
(n = 336,841)

Pharmacist-administered
(n = 17,535)

Pediatricians’ office
(n = 319,306)
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Figure 2. Forest plot of significant predictors of pharmacist-administered influenza
vaccination in children

Patient age 13-17 years old
Patient age 5-12 years old
No Age Restrictions*
Min 2-4 years old*
Min 5-12 years old (Any age with Rx)*
Min 5-12 years old*
Min 13-17 years old (Any age with Rx)*
Min 13-17 years old*
Previous Vaccine Pharmacy
Previous Vaccine Convenience care
Previous Vaccine Emergency care
Previous Vaccine Other setting
Previous Vaccine Pediatrician
South
Midwest
West
Routine exam/Follow up
Acute upper resp infection
ADHD
Strep sore throat
Cough
Fever
Extreme obesity
Otitis media
Severe developmental delay

0.1

1

10

100

Odds ratio

1000

*

Minimum age requirement for pharmacist-administered influenza vaccination.
Rx=Prescription
Note: Healthcare utilization, common pediatric conditions, and pediatric comorbidities were assessed in
6-month period prior to vaccination.
Northeast (Ref): Maine, New Hampshire, Vermont, Massachusetts, Rhode Island, Connecticut, New
York, New Jersey, Pennsylvania
Midwest: Ohio, Indiana, Michigan, Illinois, Wisconsin, Missouri, Iowa, Minnesota, North Dakota,
South Dakota, Nebraska, Kansas
South: West Virginia, District of Columbia (DC), Virginia, North Carolina, Kentucky, Maryland,
Delaware, Tennessee, South Carolina, Georgia, Florida, Alabama, Mississippi, Arkansas, Louisiana,
Oklahoma, Texas
West: Montana, Wyoming, Colorado, Utah, Idaho, Nevada, Washington, Oregon, California, Alaska,
Hawaii, New Mexico, Arizona
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Supplemental Table 1. International Classification of Diseases Version 10 (ICD-10)
codes for healthcare utilization and common pediatric diagnoses
Condition (33)

ICD 10

Routine child health examination or

Z00.121, Z00.129

Follow-up examination

Z09

Acute upper respiratory infection

J06.9
H65.01 - H65.06, H65.21 - H65.23,
H65.111 - H65.116, H65.411 H65.413, H66.001 - H66.003,
H66.011 - H66.013, H66.004 H66.006, H66.014 - H66.016, H66.11

Otitis media

- H66.13, H66.21 - H66.23

Acute pharyngitis

J02.9

Allergic rhinitis

J30.1, J30.89, J30.9

Sinusitis

J32.0 - J32.4, J32.8, J32.9
L23.0 - L23.2, L23.4 - L23.7, L23.81,
L23.89, L23.9, L24.0 - L24.3, L24.5 -

Dermatitis

L24.7, L24.81, L24.89

Attention-deficit/hyperactivity disorder

F90.0, F90.1, F90.2, F90.8

Cough

R05

Streptococcal sore throat

J02.0

Bronchitis

J20.5, J20.6, J20.9

Conjunctivitis

H10.11 - H10.13, H10.011 - H10.013,
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B30.1, B30.9
Esophageal reflux

K21.0, K21.9, P78.83
J09X1, J09X2, J09X3, J09X9, J10.1,
J10.2, J10.00, J10.01, J10.08, J10.81,
J10.82, J10.83, J10.89, J11.1, J11.2,
J11.00, J11.08, J11.81, J11.82, J11.83,

Influenza

J11.89

Gastroenteritis/colitis

K52.9

Fever

R50.83, R50.9

Constipation, unspecified

K59.00

Prophylactic vaccination

Z23
R10.13, R10.83, R10.84, R10.0,
R10.31 - R10.33,

Abdominal pain

R10.11, R10.12

Viral diseases

B33.8, B34.9

Pneumonia

J12.9, J18.0, J18.1, J18.8, J18.9
N30.00, N30.01, N30.10, N30.11,
N30.20, N30.21, N30.30, N30.31,
N30.40, N30.41, N30.80, N30.81,

Urinary tract infection, cystitis (34)

N30.90, N30.91, N39.0

96

Supplemental Table 2. International Classification of Diseases Version 10 (ICD-10)
codes for underlying health conditions which increase the risk of severe influenza
infection
Condition

ICD 10

Blood disorders (27, 35, 36)
Hemoglobinopathy

D58.2
D57.00 – D57.02, D57.1,
D57.20, D57.211, D57.212,
D57.219, D577.3, D57.40,

Sickle cell anemia

D57.411, D57.412, D57.419,
D57.80, D57.811, D57.812,
D57.819

Thalassemia major

D56.5, D56.8, D56.9

Cardiac disease (27, 35, 36)
I25.10, I25.110, I25.111,

Atherosclerotic heart disease

I25.118, I25.119
Q20.8, Q20.9, Q21.8, Q21.9 ,

Congenital heart disease

Q24.6, Q24.8, Q24.9
I25.750, I25.751, I25.758,

Coronary artery disease

I25.759, I25.811, I25.82

Cognitive disorders (28, 36)
Intellectual disability

F70, F71, F72, F73, F78, F79

Severe developmental delay

F81.0, F80.1, F80.2, F80.4,
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F80.81, F80.82, F80.89, F80.9,
F82, F88, F89
G32.0, G95.11, G95.89, G95.9,

Spinal cord injury

Q06.8, Q06.9

Hepatic conditions (36)
K74.3, K74.4, K74.5, K74.60,

Chronic liver disease with cirrhosis

K74.69

Immunocompromised conditions (27, 35, 36)
HIV/AIDS

B20

Cancer

C00.0-C96.9

Chemotherapy

Z51.0, Z51.11, Z51.12,

Chronic corticosteroid therapy

Z79.52, Z92.241

Metabolic/Endocrine conditions (27, 36, 37)
Diabetes (Type 1)

E10.65, E10.9

Diabetes (Type 2)

E11.65, E11.9

Neurologic conditions (35, 36)
G80.3, G80.0, G80.1, G80.2,

Cerebral palsy

G80.4, G80.8, G80.9

Muscular dystrophy

G71.0, G71.11
M41.40, M41.41, M41.42,

Neuromuscular disease

M41.43, M41.44, M41.45,
M41.46, M4147

Epilepsy (28)

G40B01, G40B09, G40B11,
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G40B19
E66.01, E66.09, E66.1, E66.2,

Obesity (27, 36)

E66.8, E66.9, Z68.54

Respiratory disease (27, 35, 36)
J45.20, J45.21, J45.22, J45.30,
J45.31, J45.32, J45.40, J45.41,

Asthma

J45.42, J45.50, J45.51, J45.52,
J45.990, J45.901, J45.902,
J45.909, J45.991, J45.998
J68.4, J70.1, J70.3, J84.848,

Chronic lung disease

J84.89, J84.9

Chronic obstructive pulmonary disease

J40, J41.0, J41.1, J41.8, J42
E84.0, E84.11, E84.19, E84.8,

Cystic fibrosis

E84.9

Pediatric emphysema

J43.0, J43.1, J43.2, J43.8, J43.9,
N01.0, N01.1, N01.2, N01.3,
N01.4, N01.5, N01.6, N01.7,
N01.8, N01.9, N03.0, N03.1,
N03.2, N03.3, N03.4, N03.5,

Renal disease (27, 36)

N03.6, N03.7, N03.8, N03.9,
N04.0, N04.1, N04.2, N04.3,
N04.4, N04.5, N04.6, N04.7,
N04.8, N04.9, N07.0, N07.1,
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N07.2, N07.3, N07.4, N07.5,
N07.6, N07.7, N07.8, N07.9,
N08
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MANUSCRIPT 4

Increased proportions of state-level pediatric pharmacist-administered influenza
immunization decrease influenza diagnoses

Target Journal: Journal of the American Pharmacists Association (APha)
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4.1

ABSTRACT

Background: Pharmacists are known to increase access to vaccines through increased
convenience, however, utilization of pharmacists for pediatric influenza vaccination
remains low. The impact of pharmacist-administered pediatric influenza vaccination
on pediatric influenza diagnoses is not well described.
Objectives: To evaluate the association between the state-level proportion of
pharmacist-administered pediatric influenza vaccinations on the state-level proportion
of pediatric influenza diagnoses using a retrospective ecologic study design.
Methods: We included vaccinated children from the de-identified Optum
Clinformatics® Data Mart database. The proportion vaccinated by pharmacists and
the proportion diagnosed with influenza were aggregated at the state-level during the
2016-2017 influenza season, along with potential confounders. We assessed the
association

between

state-level

pediatric

pharmacist-administered

influenza

vaccination and influenza diagnoses using backward manual stepwise beta regression.
Results: The proportion of children that received an influenza vaccine in a pharmacy
varied widely by state. At a state level, we found that influenza diagnoses among
children decrease by 6.2% (p=0.0369) per every additional 1% of children vaccinated
by a pharmacist, after controlling for potential confounding factors.
Conclusions: Pharmacists have been granted expanded authority to vaccinate children
due to the COVID-19 pandemic. While unclear how long this expanded access will
last, fewer influenza diagnoses were observed in states with higher pharmacistadministered pediatric influenza vaccination. Decreasing influenza diagnoses can help
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decrease the significant burden of influenza in children and throughout communities.
Additionally, pharmacists can play a key role as vaccine providers and reducing rates
of all vaccine-preventable diseases among children.
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4.2 INTRODUCTION
Pharmacists have been authorized to administer the influenza vaccine in all 50
states since 2009 (1-3).

As of September 2020, according to the American

Pharmacists Association (APhA) and the National Alliance of State Pharmacy
Associations (NASPA), pharmacists in all but three states (Connecticut, Florida, and
Vermont) are allowed to administer the influenza vaccine to children, however,
regulatory limitations are in place, such as state-specific minimum age requirements
(4, 5). Recently, superseding any state specific restrictions is the “Third Amendment
to Declaration Under the Public Readiness and Emergency Preparedness Act for
Medical Countermeasures Against COVID–19” (PREP Act) set forth by the United
States Health and Human Services Department (HHS), which is another expansion of
pharmacist immunization authority put into effect in August 2020. The PREP Act
authorizes pharmacists in all states to administer any FDA authorized vaccine to
children aged 3 to 18 under the for the duration of the Coronavirus Disease 2019
(COVID-19) pandemic in efforts to combat the alarming decline in routine pediatric
vaccines observed during the current pandemic (6).
Vaccination in a non-medical setting, such as a pharmacy, can improve access
to vaccination through additional convenience with expanded hours and without the
need for an appointment (2). Vaccination within a pharmacy has proven to increase
influenza vaccination coverage among adults (7, 8) as well as be more cost effective
with lower average direct costs when compared to physician offices (16%-26% less)
and other medical settings (11%-20% less) in adults (9). However, it is still unknown
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if pediatric influenza vaccinations within a pharmacy setting have an effect on
pediatric influenza diagnoses.
Therefore, the objective of this study was to evaluate the state-level association
between the proportion of pharmacist-administered pediatric influenza vaccination on
cumulative incidence of pediatric influenza diagnoses in an outpatient setting using
beta regression.

An increase in the overall state-level influenza vaccination by

pharmacists along with a decrease in outpatient influenza diagnoses may suggest that
pharmacist-administered influenza vaccination is increasing overall vaccination
coverage.
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4.3 METHODS
A retrospective ecologic study design was used to determine the association
between state level proportion of pharmacist-administered pediatric influenza
vaccination and state-level pediatric influenza outpatient diagnoses using the
Optum Clinformatics® Data Mart Database, a claims data warehouse of commercially
insured persons. Our study population included pediatric patients, less than (<) 18
years of age, who obtained an influenza vaccine between July 1, 2016 to June 30,
2017, which is representative of one influenza season (10), using Current Procedural
Terminology (CPT) codes in Supplementary Data Table 1, obtained via
Optum Clinformatics®Data Mart Database, a claims data warehouse of commercially
insured persons, containing eligibility and demographic data. Inclusion and exclusion
criteria for the study population was previously described (11). The index date was
defined as the date of vaccination, and the follow up period began on the 15th day after
vaccination to allow 2 weeks for appropriate immune response to the vaccine (10) and
continued until the end of the influenza season, which we considered June 30, 2017.
Figure 1 is a graphical depiction of the study period timeline.
In this ecologic study, each child was only counted once and then aggregated
at the state level where each state served as an individual observation. The exposure
(pharmacist-administered influenza vaccination), outcome (outpatient influenza
diagnoses, International Classification of Diseases, 10th Edition codes J09.x, J10.x,
and J11.x), and potential confounders (demographics, comorbidities, and state-level
regulations) were compiled into state-level proportions by dividing the number of
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children with each variable by the total number of pediatric patients vaccinated against
influenza in each state to calculate state-level proportions.
The independent variable, defined as the proportion of children vaccinated
within each state by a pharmacist during the study period (the number of children in a
particular state vaccinated against influenza by a pharmacist divided by all children
vaccinated against influenza within that abovementioned state) was also reported as a
proportion. The remainder of independent variables, demographic and clinical
characteristics by state proportions of the vaccinated population, as well as overall
state-level pediatric influenza immunization coverages, which were available from
previous work using the same database (12) were included as confounders. Age was
assessed as a categorical variable, mimicking the categories used by the CDC (13).
Statistical Analysis
Using statistical software for all analysis, SAS (version 9.4, SAS Institute Inc.,
Cary, NC), beta regression (14, 15) using a generalized linear model was used to
quantify the association between state-level cumulative incidence of influenza
outpatient diagnoses and the proportion of children vaccinated against influenza
within each state by a pharmacist, while controlling for confounders. Beta regression
was selected as all values being analyzed are reported as state-level proportions
between 0 and 1 (15). The cumulative incidence of influenza outpatient diagnoses
was modeled against the primary and secondary independent variables, and the
proportion of children vaccinated against influenza within each state by a pharmacist
was modeled against the secondary independent variables, potential confounders,
separately. Empty models were run using the proportion of influenza diagnoses and
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the proportion of pharmacist vaccinated, then both univariate models were run with
one independent variable at a time. The chi-squared of the difference of the -2 Log
Likelihood ratios from the empty model were compared to the univariate model and
included in the multivariate model if the chi-squared for both models was less than (<)
0.1. Potential confounders showed association with both the state-level proportion of
children vaccinated by a pharmacist and the cumulative incidence of influenza
diagnoses. Significant confounders were either statistically significant or determined
to be important to the conceptual model by the authors.
A full multivariate generalized linear regression model was used to model the
state-level cumulative incidence influenza outpatient diagnoses against proportion of
children vaccinated against influenza by a pharmacist along with significant
confounders from the univariate model. Clinical characteristics that were significant
as previously identified (11) and had significant chi-squared from the univariate with
influenza diagnosis model were also included in the multivariate model.

Also

included in the multivariate model was region and pharmacist authorization model as
categorical variables in the class statement. Multicollinearity of the initial model was
assessed using variance inflation factor (VIF), and no variables were removed.
Backward manual elimination, unconditional stepwise beta regression (15) was
utilized on the multivariate generalized linear regression model from above. Any
remaining variables that were not significant, (p-value >0.05), were removed from the
model, in a stepwise manner with the least significant removed first, until all the
variables in the multivariate model are significant (p-value ≤ 0.05) or determined
clinically relevant. Region and the pharmacist authorization model for administrating
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influenza vaccine to children within each state included in the final multivariate model
along with age group, though not statistically significant, but deemed clinically
relevant by the authors. The final model was assessed for goodness-of-fit using
pseudo R2 (15).
The parameter estimate, the change in cumulative incidence influenza
diagnoses resulting from each unit change in the independent variable, the proportion
of children vaccinated against influenza by a pharmacist, was the final output
calculated using the multivariate model above. Statistical significance was assessed
using a 2-sided test, with significance being ≤0.05, and 95% Confidence Interval (CI).
Unadjusted and adjusted odds ratio and corresponding 95% confidence interval was
reported.
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4.4 RESULTS
A total of 336,841 influenza-vaccinated children were identified in the study
population during the 2016-2017 season, with 17,535 (5.2%) vaccinated by a
pharmacist. From the total children vaccinated, 8,442 children were diagnosed with
influenza in an outpatient setting. State-level pediatric influenza vaccinations by a
pharmacist and influenza diagnoses, along with demographic and clinical
characteristics can be found in Table 1.
There were no instances of pharmacist-administered pediatric influenza
vaccination in Hawaii, South Dakota, and Wyoming within the study population and
in Washington, the pharmacist-administered influenza vaccination rate was 28.4%. In
2016, when the study population was captured, Hawaii allowed pharmacists to
vaccinate children 14 years of age and older provided they presented to the pharmacy
with a prescription from their pediatrician, and in Wyoming pharmacists had the
independent authority to vaccinate children 7 years of age and older (14).
Interestingly, children of any age can receive an influenza vaccine from a pharmacist
in both South Dakota and Washington (14). Alaska and Vermont did not have any
documented outpatient influenza diagnoses among the study population. To run the
beta regression, the above-mentioned states with 0 influenza diagnoses or 0
pharmacist-administered influenza vaccinations were changed to 0.00001.

A

sensitivity analysis was also performed by removing the state of Washington as a
potential outlier due to the very high proportion of children vaccinated within a
pharmacy. The model was repeated without Washington and the results remained
consistent with the original model, therefore, Washington remained in the final model.
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The unadjusted and adjusted parameter estimates for the association between
pharmacist-administered pediatric influenza vaccination and influenza diagnoses and
corresponding 95% confidence intervals (CIs) are reported (Table 2). After removing
non-significant variables, the final multivariable model included 8 independent
variables. Pharmacist-administered influenza vaccination, pharmacist authorization
model age restriction (added as a class), chronic pulmonary disease (COPD), routine
health exam or follow up, prophylactic vaccination, and fever were all statistically
significant (p<0.05). Although not statistically significant, age group and geographic
region were retained in the model due to epidemiologic relevance of age (15) and
geographic region (16, 17).
The parameter estimate for the proportion of children vaccinated by a
pharmacist was -6.19 (95% CI -11.98 to -0.40, p=0.0369), corresponding to a
significant decrease of 6.2% influenza diagnoses for every additional 1% of children
vaccinated in a pharmacy.
A sensitivity analysis was performed by re-running the analysis using both the
5-12-year-old age group and the 13-17-year-old age group separately. Independently,
both age groups did not result in observed significant decreases in influenza diagnoses
with respect to proportion of pharmacist-administered pediatric influenza vaccination
rates.
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4.5 DISCUSSION
Our state-level ecologic study provides supportive evidence that higher rates of
pharmacist-administered pediatric influenza vaccination decreases pediatric outpatient
influenza diagnoses by 6.2% for every 1% increase in vaccination by a pharmacist. It
is possible that, by expanding access to vaccine access due to regulations granting
authority to pharmacists to vaccinate children, influenza vaccination coverage may be
increasing, as has been previously observed in adults (7, 8). This expanded access to
vaccination has shown to reduce influenza diagnoses.
In previous work, older age was identified as a significant driver of pediatric
pharmacist-administered influenza vaccination, where children 13 to 17 years old and
5 to 12 years old were 92 times and 35 times more likely to use pharmacy based
influenza vaccination services, respectively and utilization of pharmacists as
vaccinators has been shown to primarily take place in children between the ages of 1317 years old, 57.6%; and 5-12 years old, 41.9% using the same influenza season and
study population presented in this research (11). This 13-17-year-old age group was
also associated with the highest increase in influenza vaccination rates over 7
influenza seasons from 2010-2017, increasing annually by 6%, followed by an annual
increase in pharmacist-administered influenza vaccination of 1.9% in children 5-12
years old (18). Overall, pharmacist-administered pediatric influenza vaccination has
been shown to increase by 19.2% annually from 2010-2017, where influenza
vaccination within a pediatrician’s office decreased by 0.9% (19). Particularly in the 5
to 12 year old age group and 13-17-year old age group, these increases in pharmacistadministered pediatric influenza vaccination by 17.1% and 15.2% respectively (19),
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and overall increases in influenza vaccination rates (18), is contributing partially to
increased vaccination.
Considering the aforementioned findings, this study showed that pharmacists
may have been providing additional influenza immunizations to children, who would
not have otherwise been vaccinated, which therefore resulted in a decrease in
transmission and diagnosis of the influenza virus in children. A Canadian survey
study among adults from 2013 showed that 25% of adult patients that were vaccinated
by pharmacists were not yearly influenza vaccine recipients, 28% reported that if
pharmacist-administered vaccination was not available they would not have received
the influenza vaccination, and 99% would recommend being vaccinated by a
pharmacist to their family and friends (20).
The cumulative proportion of children vaccinated within a pharmacy for all
states is very low; 5.2%, as well as state-level proportions of most comorbidities and
some healthcare utilization. This may attribute to the low numbers of comorbidities
included in the multivariate model. It would be interesting to run a similar model in
adults, as adults are known to use pharmacies as places of vaccination more
frequently, around 28% (7) and are more likely to present with comorbidities. Statelevel variations may change based on geographical differences and patient
preferences, rather than corresponding minimum age restrictions.
The burden of the influenza virus and disease among children is considerable
(21, 22) and the influenza vaccine is recommended by the Centers for Disease Control
and Prevention (CDC) and the Advisory Committee on Immunization Practices
(ACIP) for everyone 6 months and older (23-28) as a safe and effective way to prevent
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the influenza disease and influenza-related complications (28-30). During the 20162017 influenza season, 8.8 million symptomatic illnesses, 5 million medical visits,
over 34,000 hospitalizations, and over 250 deaths were estimated among children less
than 18 years old in the United States (31). Approximately 10%-15% of children
infected with influenza will need medical care and children less than 2 are at higher
risk for hospitalization (22). The influenza virus is also responsible for a tremendous
economic burden, including direct costs for healthcare visits and treatment, which can
range from $114 for a pediatric outpatient visit to upwards of $7,300 for a pediatric
hospitalization (32), as well as indirect costs of missed school and caregiver work due
to illness. Two years after the introduction of pharmacist-administered influenza
immunization in Ontario, Canada during the 2013-2014 influenza season, the county
observed an increase in immunization rate by about 3% of the total population, with
pharmacists providing influenza vaccines to both new patients and patients who may
have previously been vaccinated elsewhere, resulting in a potential savings of $2.3
million in direct and indirect influenza related costs (33).
Children are not only at increased risk for severe infection and complications
(34), but they are also well known for transmitting the disease throughout their
households and communities (34-38) and vaccinating children has been shown to
reduce illness among children, as well as reduce influenza illness and hospitalizations
in older adults and the overall impact of influenza within the community (22, 35-39).
Our study provides evidence that states with higher proportions of pharmacistadministered pediatric influenza vaccination are associated with a lower cumulative
incidence of influenza diagnoses among a commercially insured vaccinated pediatric
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population.

Pharmacists as vaccinators have the ability to decrease influenza

diagnoses among children, and in turn, lesson some of the burden caused by the
disease. It would be interesting to evaluate if overall influenza diagnoses of both
children and adults is affected by increased utilization of pharmacists as vaccinators.
Recently, pharmacists have been granted vaccination authority in all states to
children between the ages of 3 and 18 under the PREP Act to administer any FDA
authorized vaccine (6).

Because of this, it is likely that children will be using

pharmacists more as vaccinators for routine childhood vaccines, in addition to
influenza vaccine, mainly as routine preventative care pediatrician visits may still be
disrupted (40). Our study proves that pharmacist-administered pediatric influenza
vaccination is an effective way to decrease the number of influenza diagnoses. We
expect pharmacist-administered vaccination for other routine childhood vaccines will
decrease infection rates for other vaccine preventable diseases as well. This will be a
critical step toward combating the major decline in routine pediatric vaccinations
observed predominantly in the beginning of the COVID-19 pandemic.
Limitations
There are several limitations from the dataset used, a single commercially
insured population within the United States, which does not represent the approximate
30 million children with Medicaid (41). We have assumed that influenza vaccination
claims, categorization of provider setting, and claims of the clinical comorbidities of
interest are accurately and consistently coded in the claims database. Only the first
influenza vaccine in each season was included and it is possible a different provider
setting was used in cases where children received a second vaccine.
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Patient

demographics and clinical characteristics at the state-level were evaluated from data
available from the database. Other confounders, body mass index, income, and health
literacy could not be assessed. One major potential confounder, race, was not
available in our database and therefore was not included as a potential confounder,
potentially influencing both pharmacist-administered pediatric influenza vaccination
and influenza diagnoses.
Additionally, it is possible to treat influenza at home with over the counter
medications, without seeking medical attention for diagnosis.

These cases of

influenza would not have an associated diagnosis and therefore not be captured using
this study design.

Contracting influenza virus can potentially be avoided with

infection control measures, such as proper hand hygiene and avoiding exposure to the
virus (29), which was an uncontrollable covariate in this study. Influenza peaks can
also be affected by environmental factors, such as temperature and precipitation, that
vary by state and were not considered (42).
Cumulative incidence influenza diagnoses as well as individual demographic
and comorbidity data were aggregated and reported at the state-level. Due to the
ecologic study design, this study is subject to confounding by group, where each state
may have a different rate of disease regardless of vaccination status (43). Ecological
fallacy may also present bias of interpretation, which is when data from groups, in this
case different states, is interpreted at an individual level (44). However, this study is
designed to evaluate each state and the age restrictions and vaccination rates rather
than individuals, which should minimize this potential limitation. Lastly, the beta
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regression model used in this study assumes that the relationship between influenza
vaccination rate and influenza-related hospitalization is linear.
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4.6 CONCLUSION
We observed a significant decrease in influenza diagnoses among states with
higher proportions of children vaccinated by a pharmacist. We also observed, from
previous studies, that the rate of pharmacist-administered influenza has been
increasing in recent years (19). These increases in pharmacist-administered pediatric
influenza vaccination are likely contributing to increased influenza vaccination and
decreased influenza diagnoses for all children. Pharmacists primarily administer
influenza vaccines to children of older age groups (11, 19), where increases in
utilization over the past decade have been observed (18).

Decreasing influenza

diagnoses through pharmacist-administered pediatric influenza vaccination can help
decrease the significant burden of influenza in children and throughout communities
(35, 36, 39). During the current COVID-19 pandemic, pharmacists will likely be
vaccinating more children of all age groups for routine childhood vaccines as well as
influenza and COVID-19 vaccines when they become available (6). We presume this
expanded access to vaccination by pharmacists will decrease infection rates for other
vaccine preventable diseases as well.
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4.8 TABLES AND FIGURES
Table 1. State-level pediatric influenza vaccination rates, pharmacist administered
vaccination rate among those vaccinated, and influenza diagnosis rate
Proportion of

Proportion of

Proportion of

children receiving

children receiving

children with

an influenza vaccine

an influenza

influenza

in any setting (%)

vaccine in a

diagnoses (of those

(18)

Pharmacy (%)

vaccinated) (%)

Alaska (AK)

14.1

3.3

0

Alabama (AL)

26.9

6.8

4.2

Arkansas (AR)

36.1

8.8

2.4

Arizona (AZ)

25.4

9.1

1.1

California (CA)

31.5

4.5

0.7

Colorado (CO)

40.5

9.4

1.4

Connecticut (CT)

50.1

0.1

3.8

District of Columbia (DC)

44.5

1.5

1.8

Delaware (DE)

37.3

7.2

0.9

Florida (FL)

24.4

0.3

2.9

Georgia (GA)

28.6

4.9

3.7

Hawaii (HI)

30.3

0

4.3

Iowa (IA)

36.3

6.3

1.8

Idaho (ID)

18.2

3.3

0.2

Illinois (IL)

30.8

5.3

2.0

Indiana (IN)

26.2

5.1

1.9

State
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Kansas (KS)

33.0

7.9

1.9

Kentucky (KY)

32.0

3.8

2.3

Louisiana (LA)

26.6

9.1

4.7

Massachusetts (MA)

47.6

0.1

2.0

Maryland (MD)

40.3

5.6

3.3

Maine (ME)

26.8

8.6

0.3

Michigan (MI)

29.9

8.7

1.9

Minnesota (MN)

43.2

0.8

1.3

Missouri (MO)

32.5

5.7

2.3

Mississippi (MS)

17.8

10.9

4.6

Montana (MT)

23.6

3.5

1.0

North Carolina (NC)

37.9

3.2

4.5

North Dakota (ND)

37.7

0.1

1.5

Nebraska (NE)

45.0

8.4

1.3

New Hampshire (NH)

39.9

6.0

1.8

New Jersey (NJ)

50.0

2.0

4.5

New Mexico (NM)

20.8

10.6

1.3

Nevada (NV)

18.1

10.2

0.6

New York (NY)

46.7

0.1

4.8

Ohio (OH)

33.3

5.4

1.5

Oklahoma (OK)

27.8

9.4

5.1

Oregon (OR)

39.3

3.4

0.6

Pennsylvania (PA)

42.0

3.4

1.4
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Rhode Island (RI)

52.6

0.1

2.0

South Carolina (SC)

26.9

3.5

5.2

South Dakota (SD)

42.6

0

3.9

Tennessee (TN)

30.2

8.5

3.6

Texas (TX)

34.9

7.8

3.7

Utah (UT)

34.6

6.3

0.6

Virginia (VA)

40.6

8.2

4.4

Vermont (VT)

41.5

2.0

0

Washington (WA)

26.6

28.4

1.2

Wisconsin (WI)

34.9

5.0

0.7

West Virginia (WV)

25.0

1.6

3.4

Wyoming (WY)

18.8

0

2.7

33.4% ± 9.3%

5.4% ± 4.7%

2.3% ± 1.5%

Mean ± standard
deviation

126

Table 2. Association between pharmacist-administered pediatric influenza vaccination and influenza diagnoses
Unadjusted, Dependent

Unadjusted, Independent

Adjusted, Dependent

Variable: Influenza

Variable: Pharmacist-

Variable:

Diagnoses

Administered Vaccination

Influenza Diagnoses

Estimate
Pediatric pharmacist-administered
influenza vaccinations

Chi-squared
p-value

-0.06

Estimate

Chi-squared
p-value

1.000

Estimate

P-value

-6.1899

0.0369
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Age Group
6 months to 4 years

Ref

5-12 years old

-4.53

13 to 17 years old

6.53

Ref
0.1637

11.58

Ref
0.0341

5.87

4.41

0.3499

3.73

0.2189

Region
Northeast

Ref

Midwest

0.32

South

0.90

West

-0.33

Ref

Ref

0.55
<0.0001

0.98
0.6

0.0583

-0.26

0.2251

0.07

0.7676

-0.54

0.0987

Pharmacist Authorization Model Age Restriction
Does not allow, minimum age 18

Ref

Ref

Ref
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No Age Restriction

0.05

1.54

0.70

0.0183

Min 2 to 4 years old

-0.10

1.93

0.79

0.2020

Min 5-12 years old, AA

0.45

1.38

0.27

0.3150

Min 5-12 years old

0.07

0.38

0.1466

Min 13-17 years old, AA

0.85

1.42

0.74

0.0609

Min 13-17 years old

1.01

-0.16

0.19

0.5767

0.3397

0.74

0.0010

Healthcare Utilization and Common Pediatric Conditions
Routine child health exam/Follow up

8.16

0.0006

-5.79

0.0610

10.20

<0.0001

Fever

23.23

<0.0001

-5.13

0.5071

16.00

0.0003

Prophylactic vaccination

-7.67

0.0364

-10.56

0.0180

-8.37

0.0053

123.82

<0.0001

-70.56

0.0629

70.58

0.0087

Other Less Common Pediatric Conditions
Chronic pulmonary disease (COPD)

NOTE: Unit of analysis modeled, state-level proportions to 0.001.

Figure 1. Study Period Timeline
Index Date – Influenza Vaccination Date
(July 1, 2016 – June 30, 2017)
Day 0
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Inclusion Assessment Window
Pediatric Patients
< 18 years of age
Covariate Assessment Window
Baseline conditions and demographics
Days [-365, -1] Previous Flu Vaccine
Days [-182.5, -1] Comorbidities
Exclusion Assessment
Window
(allow 14 days for
immune response)
Days [0, 14]

Follow Up Period
Influenza-related diagnosis
Day 15 through June 30, 2017

Time

Supplemental Table 1. International Classification of Diseases Version 10 (ICD-10)
codes for healthcare utilization and common pediatric diagnoses
Condition (33)

ICD 10

Routine child health examination or

Z00.121, Z00.129

Follow-up examination

Z09

Acute upper respiratory infection

J06.9
H65.01 - H65.06, H65.21 - H65.23,
H65.111 - H65.116, H65.411 H65.413, H66.001 - H66.003,
H66.011 - H66.013, H66.004 H66.006, H66.014 - H66.016, H66.11

Otitis media

- H66.13, H66.21 - H66.23

Acute pharyngitis

J02.9

Allergic rhinitis

J30.1, J30.89, J30.9

Sinusitis

J32.0 - J32.4, J32.8, J32.9
L23.0 - L23.2, L23.4 - L23.7, L23.81,
L23.89, L23.9, L24.0 - L24.3, L24.5 -

Dermatitis

L24.7, L24.81, L24.89

Attention-deficit/hyperactivity disorder

F90.0, F90.1, F90.2, F90.8

Cough

R05

Streptococcal sore throat

J02.0

Bronchitis

J20.5, J20.6, J20.9

Conjunctivitis

H10.11 - H10.13, H10.011 - H10.013,
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B30.1, B30.9
Esophageal reflux

K21.0, K21.9, P78.83
J09X1, J09X2, J09X3, J09X9, J10.1,
J10.2, J10.00, J10.01, J10.08, J10.81,
J10.82, J10.83, J10.89, J11.1, J11.2,
J11.00, J11.08, J11.81, J11.82, J11.83,

Influenza

J11.89

Gastroenteritis/colitis

K52.9

Fever

R50.83, R50.9

Constipation, unspecified

K59.00

Prophylactic vaccination

Z23
R10.13, R10.83, R10.84, R10.0,
R10.31 - R10.33,

Abdominal pain

R10.11, R10.12

Viral diseases

B33.8, B34.9

Pneumonia

J12.9, J18.0, J18.1, J18.8, J18.9
N30.00, N30.01, N30.10, N30.11,
N30.20, N30.21, N30.30, N30.31,
N30.40, N30.41, N30.80, N30.81,

Urinary tract infection, cystitis (34)

N30.90, N30.91, N39.0
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Supplemental Table 2. International Classification of Diseases Version 10 (ICD-10)
codes for underlying health conditions which increase the risk of severe influenza
infection
Condition

ICD 10

Blood disorders (27, 35, 36)
Hemoglobinopathy

D58.2
D57.00 – D57.02, D57.1,
D57.20, D57.211, D57.212,
D57.219, D577.3, D57.40,

Sickle cell anemia

D57.411, D57.412, D57.419,
D57.80, D57.811, D57.812,
D57.819

Thalassemia major

D56.5, D56.8, D56.9

Cardiac disease (27, 35, 36)
I25.10, I25.110, I25.111,

Atherosclerotic heart disease

I25.118, I25.119
Q20.8, Q20.9, Q21.8, Q21.9 ,

Congenital heart disease

Q24.6, Q24.8, Q24.9
I25.750, I25.751, I25.758,

Coronary artery disease

I25.759, I25.811, I25.82

Cognitive disorders (28, 36)
Intellectual disability

F70, F71, F72, F73, F78, F79

Severe developmental delay

F81.0, F80.1, F80.2, F80.4,
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F80.81, F80.82, F80.89, F80.9,
F82, F88, F89
G32.0, G95.11, G95.89, G95.9,

Spinal cord injury

Q06.8, Q06.9

Hepatic conditions (36)
K74.3, K74.4, K74.5, K74.60,

Chronic liver disease with cirrhosis

K74.69

Immunocompromised conditions (27, 35, 36)
HIV/AIDS

B20

Cancer

C00.0-C96.9

Chemotherapy

Z51.0, Z51.11, Z51.12,

Chronic corticosteroid therapy

Z79.52, Z92.241

Metabolic/Endocrine conditions (27, 36, 37)
Diabetes (Type 1)

E10.65, E10.9

Diabetes (Type 2)

E11.65, E11.9

Neurologic conditions (35, 36)
G80.3, G80.0, G80.1, G80.2,

Cerebral palsy

G80.4, G80.8, G80.9

Muscular dystrophy

G71.0, G71.11
M41.40, M41.41, M41.42,

Neuromuscular disease

M41.43, M41.44, M41.45,
M41.46, M4147

Epilepsy (28)

G40B01, G40B09, G40B11,
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G40B19
E66.01, E66.09, E66.1, E66.2,

Obesity (27, 36)

E66.8, E66.9, Z68.54

Respiratory disease (27, 35, 36)
J45.20, J45.21, J45.22, J45.30,
J45.31, J45.32, J45.40, J45.41,

Asthma

J45.42, J45.50, J45.51, J45.52,
J45.990, J45.901, J45.902,
J45.909, J45.991, J45.998
J68.4, J70.1, J70.3, J84.848,

Chronic lung disease

J84.89, J84.9

Chronic obstructive pulmonary disease

J40, J41.0, J41.1, J41.8, J42
E84.0, E84.11, E84.19, E84.8,

Cystic fibrosis

E84.9

Pediatric emphysema

J43.0, J43.1, J43.2, J43.8, J43.9,
N01.0, N01.1, N01.2, N01.3,
N01.4, N01.5, N01.6, N01.7,
N01.8, N01.9, N03.0, N03.1,
N03.2, N03.3, N03.4, N03.5,

Renal disease (27, 36)

N03.6, N03.7, N03.8, N03.9,
N04.0, N04.1, N04.2, N04.3,
N04.4, N04.5, N04.6, N04.7,
N04.8, N04.9, N07.0, N07.1,
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N07.2, N07.3, N07.4, N07.5,
N07.6, N07.7, N07.8, N07.9,
N08
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Supplementary Table 1. Current Procedural Terminology (CPT) codes for influenza
vaccination
CPT
Code

Description

9952

PROPH VACCINATION AGAINST FLU

90470

H1N1 IMMUNIZATION, IM AND INTRANASAL

90630

FLU VACC IIV4 NO PRESERV ID

90653

IIV ADJUVANT VACCINE IM

90654

FLU VACC IIV3 NO PRESERV ID

90655

IIV3 VACC NO PRSV 0.25 ML IM

90656

IIV3 VACC NO PRSV 0.5 ML IM

90657

IIV3 VACCINE SPLT 0.25 ML IM

90658

IIV3 VACCINE SPLT 0.5 ML IM

90659

FLU VACCINE WHOLE IM

90660

LAIV3 VACCINE INTRANASAL

90661

CCIIV3 VAC NO PRSV 0.5 ML IM

90662

IIV NO PRSV INCREASED AG IM

90663

FLU VACC PANDEMIC H1N1

90664

LAIV VACC PANDEMIC INTRANASAL

90666

FLU VAC PANDEM PRSRV FREE IM

90667

IIV VACC PANDEMIC ADJUVT IM

90668

IIV VACCINE PANDEMIC IM
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90672

LAIV4 VACCINE INTRANASAL

90673

RIV3 VACCINE NO PRESERV IM

90674

CCIV4 VAC NO PRSV 0.5 ML IM

90682

RIV4 VACC RECOMBINANT DNA PRSRV ANTIBIO FREE IM

90685

IIV4 VACC NO PRSV 0.25 ML IM

90686

IIV4 VACC NO PRSV 0.5 ML IM

90687

IIV4 VACCINE SPLT 0.25 ML IM

90688

IIV4 VACCINE SPLT 0.5 ML IM

90689

IIV4 VACC INACTIVATED, ADJUVN, PRSV FREE 0.25 ML IM

90724

INFLUENZA IMMUNIZATION

90737

INFLUENZA B IMMUNIZATION

90756

IIV4 VACC INACTIVATED ABX FREE 0.5 ML

3E01340 INTRO FLU VACCINE SUBQ TISSUE PC
4035F

INFLUENZA IMM REC

4037F

INFLUENZA IMM ORDER/ADMIN

G0008

ADMINISTRATION INFLUENZA VIRUS VACC

G8108

PT DOC RECV FLU VACC DUR FLU SEASON

G9141

INFLUENZA A H1N1 IMMUNIZATION ADMIN

G9142

INFLUENZA A H1N1 VACCINE ANY ROUTE

Q0034

INFLUENZA VACCI; MEDICAR

Q2033

INF VACC RECOMB HEMAGGLUTININ AG IM

Q2034

FLU VIRUS VAC SPLIT VRS IM AGRIFLU

Q2035

FLU VACC SPLIT 3 YRS & > IM AFLURIA
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Q2036

FLU VACC SPLIT 3 YR & > IM FLULAVAL

Q2037

FLU VACC SPLIT 3 YR & > IM FLUVIRIN

Q2038

FLU VACC SPLIT 3 YRS & > IM FLUZONE

Q2039

INFLUENZA VIRUS VACCINE NOS
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